1 BEFORE THE INSURANCE COMMISSIONER OF THE STATE OF IOWA 2 3 In the matter of the ) application for ) 4 acquisition of control of) AETNA BETTER HEALTH OF ) 5 IOWA, INC., and AETNA ) HEALTH OF IOWA, INC., ) PUBLIC HEARING 6 by ) CVS HEALTH CORPORATION ) COPY 7 and CVS PHARMACY, INC., ) 8 -----) 9 10 11 The above-entitled matter came on for 12 public hearing commencing at 9:30 a.m., 13 October 24, 2018, at the Iowa Insurance Division, Two Ruan Center, Fourth Floor, 14 15 Des Moines, Iowa. 16 17 18 BEFORE: DOUG OMMEN, Iowa Insurance Commissioner 19 20 21 22 23 Reported by: Kristi L. Miller 24 25

Page 2	2
--------	---

1	А	PPEARANCES
2	Insurance Divi	sion by: JOHN D. HUNTER
3		MAGARET A. HIBBS Attorneys at Law
4		Brown Winick Law Firm 666 Grand Avenue
5		Suite 2000 Des Moines, IA 50309
6		(515) 242-2400
7	CVS by:	STEVEN T. WHITMER
8		TIMOTHY S. FARBER Attorneys at Law
9		Locke Lord, LLP 111 South Wacker Drive
10		Chicago, IL 60606 (312) 443-0532
11		
12		MARK C. DICKINSON Attorney at Law
13		Nyemaster Goode, P.C. 700 Walnut Street
14		Suite 1600M Des Moines, IA 50309
15		(515) 283-3100
16	Aetna by:	DANIEL KRANE
17		Attorney at Law Drinker Biddle & Reath LLP
18		One Logan Square, Suite 2000 Philadelphia, PA 19103
19		(215) 988-2488
20		MATTHEW McDERMOTT
21		Attorney at Law Belin, McCormick, P.C.
22		666 Walnut Street, Suite 2000 Des Moines, IA 50309
23		(515) 243-7100
24		
25		

Page 3

1	APPEARANCES CONINUED
2	
3	Also Present:
4	Jim Armstrong, Deputy Commissioner, IID Kim Cross, Chief Examiner, IID
5	Sonya Sellmeyer, Consumer Advocate, IID Chance McElhaney, Communications Director, IID
6	Eric Konz, IID Florence Crisp, CVS Health
7	Gregory Martino, Aetna Ann Frohman, Aetna
8	Michelle Matiski, Aetna Larry Lewis, Aetna
9	Mike St. Clair, CVS Scott Sundstrom, Wellmark
10	Brian Lombardi, Bank of America Kristi Traynor, Attorney General's Office
11	Ryan Lynch, Reorg Courtney Gordon, LS2 Group
12	Ed Roberts, CT Financial News David Pickering, Pentwater Capital
13	Kiva Garen, Surveyor Capital
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

Page 4	4
--------	---

1		INDEX	
2	Examination by:		Page
3	Mr. Whitmer	Florence Crisp	17
4	Mr. Hunter	Florence Crisp	49
5	Mr. Whitmer	Gregory Martino	57
6			
7			
8	Exhibit	Marked/Offered/Ad	mitted
9	A	15	
10	В	15	
11	С	72	
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

Page	5
------	---

1	THE COMMISSIONER: We are on the
2	record. This is a matter on the record and so
3	I will begin with some opening comments and
4	then we can proceed with the business.
5	I am Commissioner Doug Ommen,
6	and my role in this proceeding is to serve as a
7	presiding officer and decision-maker.
8	I'll briefly explain the
9	administrative process to any of you who are
10	attending who may be unfamiliar with it.
11	The notice of hearing in the
12	matter of the Joint Application of CVS Health
13	Corporation and CVS Pharmacy, Inc., for the
14	acquisition of control through the purchase of
15	Aetna Better Health of Iowa, Inc., and Aetna
16	Health of Iowa, Inc., was issued previously in
17	conformance with Chapter 17A requirements.
18	The notice included but was not
19	limited to the following information: The date
20	and time, location, nature, the nature of the
21	hearing, our legal authority, and the issues
22	presented, as well as the statutes and rules
23	involved.
24	Today's proceeding is an
25	administrative contested case proceeding which

1 will be conducted under the Iowa Administrative 2 Procedures Act, Iowa Code Chapter 17A, and the 3 Insurance Division's Implementing Rules 4 relative to this proceeding found in Iowa 5 Administrative Code, Volume 191, Chapter 3. 6 Iowa administrative hearings are 7 generally less formal than district court hearings. As the presiding officer and 8 commissioner, I will conduct the hearing and 9 rule on evidentiary issues and any motions 10 11 submitted. In addition, I will issue any 12 orders and rulings necessary to ensure the orderly conduct of the hearing. 13 14 The hearing will be conducted 15 along the following lines: The parties will be 16 given a few minutes to make opening statements 17 if they wish. The parties will then present their cases. Witnesses will be sworn or 18 19 affirmed by the court reporter and will be 20 subject to examination and cross-examination. 21 Members of the public are 2.2 entitled to participate in this process. At 23 this time I haven't been notified there are any 24 members of the public here, but should there 25 be, we want to make sure that they are given

1 the opportunity to be heard.

If there is anyone who does wish to appear, they will be allowed to attend and give whatever testimony or comment they wish. The receptionist has been advised to escort any member of the public to the hearing room as soon as they arrive.

8 I may limit questioning in a 9 manner consistent with the law, and when all 10 parties and witnesses have been heard, the 11 parties will be given an opportunity for final 12 arguments.

13 Please keep in mind that 14 irrelevant, immaterial, or unduly repetitious evidence will be excluded. Because the rules 15 16 of evidence are more relaxed in administrative 17 cases, relevant evidence will generally be admitted subject to objection. All objections 18 must be timely and stated on the record. 19 20 Documentary evidence may be 21 received through copies of excerpts if the 2.2 originals are not available. I may take 23 official notice of all facts of which judicial 24 notice may be taken and other facts within the 25 specialized knowledge of the division.

Page 8

1 The division's experience, 2 technical competence, and specialized knowledge 3 may be used in evaluating the evidence 4 presented. Because the division is the 5 6 primary officer in this hearing, I serving as 7 commissioner, and therefore my decision will be 8 the final agency action for purposes of Iowa 9 Code Chapter 17A. 10 If anyone has a question as we go along, please raise your hand. We will then 11 12 go off the record and address your guery and I 13 will make a determination as to whether or not 14 it needs to be on the record. 15 We may take a short break every 16 30 to 45 minutes, should it go that long, or so 17 if it runs so that the court reporter and all 18 parties have a chance to review their notes and collect thoughts. 19 20 For witnesses, please speak 21 slowly and clearly so the court reporter who 2.2 sits here to my left can accurately pick up our 23 testimony. Nodding or shaking your head or 24 giving a nonresponsive answer is unacceptable, 25 and if we have a problem with that, I will ask

someone to come forward and ask you to restate
your answer.

3 Also, please wait to answer a question until the full question has been 4 presented to you. It's very difficult for a 5 6 court reporter to capture testimony when the person asking the question and the person 7 8 seeking to answer is speaking simultaneously. 9 If the court reporter cannot 10 hear you or otherwise capture -- is unable to 11 capture your testimony, she may ask you to 12 repeat your answer. All right. With those -- that 13

14 background instruction, I think we're ready to I would like to go ahead and rule on 15 proceed. 16 several pro hac vice applications, but before 17 we do that, let's go ahead and do entries of 18 appearance for the benefit of the record. So 19 let's go ahead and begin here to my left. 20 MR. DICKINSON: Mark Dickinson 21 of Nyemaster Goode. I'm here today as local 2.2 counsel for CVS, the applicant, and I am the 23 sponsor of the motions pro hoc vice for 24 Mr. Farber and Mr. Whitmer.

25 THE COMMISSIONER: It's good to

1 see you again. Let's go ahead and 2 continue with -- recognizing there's some 3 motions pending, let's continue with entries of 4 appearance. MR. FARBER: I am Tim Farber. 5 6 I'm from the outside law firm of Locke Lord, 7 and I also represent CVS, the applicant. 8 THE COMMISSIONER: Good to meet 9 you, Mr. Farber. 10 MR. WHITMER: Good morning. My 11 name is Steven Whitmer. I'm with the firm 12 Locke Lord as well and also represent CVS 13 Health. 14 MS. CRISP: My name is Florence 15 Crisp, in-house counsel to CVS Health. 16 MR. MARTINO: Gregory Martino 17 with Aetna. 18 MR. McDERMOTT: I'm Matt 19 McDermott with the Belin Law Firm. I'm local 20 counsel for Aetna, and I am sponsor of the 21 pro hac vice motion of Dan Krane. 2.2 MR. KRANE: Hi. Dan Krane from 23 Drinker, Biddle & Reath, outside counsel to 24 Aetna. 25 THE COMMISSIONER: All right.

1 Given we can't handle the entries with regards 2 to those that are appearing pro hac vice or 3 seeking that, I will go ahead and take those 4 issues up and order that the application pro 5 hac vice be approved and that you are 6 authorized to appear on behalf of your 7 respective clients today. And that would include those 8 that were mentioned, and I have in front of me 9 10 Mr. Whitmer, Mr. Farber, and Mr. Krane. So 11 those -- you are authorized to appear in 12 today's proceedings. 13 Again, thank you very much for 14 being here. There are others here also, so I'd like to continue through the entries of 15 16 appearance. To my right here is 17 Mr. Armstrong with the division. So if you 18 19 would proceed, and we'll go around the table, 20 just again for the benefit of the record. 21 Jim Armstrong MR. ARMSTRONG: 2.2 with the insurance division. 23 MS. CROSS: Kim Cross, insurance 24 division. 25 MR. HUNTER: John Hunter, Brown

2 division. 3 MS. HIBBS: Maggie Hibbs, Brown Winick Law Firm, representing the insurance 4 5 division. 6 MR. LYNCH: Ryan Lynch. I'm a 7 reporter at Reorg. 8 MS. GORDON: Courtney Gordon with LS2 Group, just observing. 9 Eric Konz, Iowa 10 MR. KONZ: 11 Insurance Division. 12 MR. MCELHANEY: Chance 13 McElhaney, Iowa Insurance Division. 14 THE COMMISSIONER: And I know in the back of the room there are some others 15 16 assembled. If you're here on behalf of any 17 particular party that is involved in this 18 proceeding, I'll give you the opportunity to 19 make your entry of appearance. 20 If you're here simply to 21 spectate, you don't need to do that. So among 2.2 those of you in the back of the room, would you 23 like to be a part of the record? 24 MS. FROHMAN: Ann Frohman on behalf of Aetna. 25

1

THE COMMISSIONER: Good morning. 1 2 MS. MATISKI: Michelle Matiski, 3 in-house counsel with Aetna. 4 THE COMMISSIONER: Good morning 5 to both of you. All right. Again, seeing none 6 others, I know there are others here in the 7 room and, again, as the proceeding -- as we move forward, if you would like to be 8 recognized, we will do that at that time. 9 10 So let's go ahead and proceed 11 with your evidence, please. 12 MR. DICKINSON: At this time T 13 would like to recognize Steve Whitmer, who will 14 conduct the direct examination of the two witnesses on behalf of CVS. 15 16 THE COMMISSIONER: You may 17 proceed. 18 MR. WHITMER: Thank you, 19 Commissioner. Obviously we are here today to 20 address the CVS-Aetna transaction. 21 You'll be hearing from two 2.2 First, Florence Crisp, who is witnesses. 23 sitting to my left, who serves as the senior legal counsel for CVS Health. And just to her 24 25 left is Gregory Martino, who serves as the

assistant vice president for state government
 relations for Aetna.

The witnesses will be focusing today, after providing a little bit of background on the transaction and their role in the transaction will be focusing on how all six of the factors set forth in Iowa Code Section 521A.3(4)(a)(1-6), they will be addressing each of those factors here for you today.

10 As a preliminary matter, we have 11 two sets of documents that we are going to 12 request be moved into evidence today. We have 13 two disks, thumb drives. One of them contains 14 our collective hearing submissions in a confidential format, and the second contains 15 16 our submissions in a nonconfidential or public 17 format.

18 The information on the disks 19 have been coordinated between us and counsel 20 for the department, and they contain the Form A 21 that has been submitted in this matter and also 22 the affidavits of Ms. Crisp and Mr. Martino 23 with respect to this matter. All this 24 information is on there.

We respectfully request at this

25

time that both the thumb drives be admitted 1 2 into evidence with the confidentiality 3 restrictions being recognized as well. 4 THE COMMISSIONER: All right. 5 Do you -- have the thumb drives been marked as 6 exhibits? 7 MR. WHITMER: They have been marked as Iowa Public Form A and Confidential 8 9 Regulatory -- Regulator Only Iowa Form A, and 10 we can submit them to the court reporter for 11 formal marking. 12 THE COMMISSIONER: Let's qo 13 ahead and have them marked. 14 (Exhibits A-B were marked for 15 identification by the reporter.) 16 THE COMMISSIONER: They have been identified. Are there any objections to 17 the receipt of these two exhibits? 18 19 Hearing no objection, the exhibits will be received. I think they're 20 21 currently again marked as Confidential 2.2 Regulator Only Iowa Form A and Iowa Public 23 Form A. So these two exhibits are received 24 into evidence. 25 During your questioning of your

1 witnesses, will you be referring to documents 2 on this? Because clearly I don't have a 3 computer in front of me, so unless you're 4 prepared to make them available to me visually, 5 you're going to have to help me here because 6 normally what I have is I have a very large 7 stack of papers in these proceedings, so this is my first electronic exhibit having been 8 9 received. 10 I'm not against it, but I hope 11 you'll be able to elicit some information from 12 your witnesses that will prevent me from 13 needing to go get my computer right now. 14 MR. WHITMER: We will, 15 Commissioner. We will definitely do that. 16 THE COMMISSIONER: All right. 17 With that, who will be your first witness? MR. WHITMER: Our first witness 18 19 we'd like to call is Florence Crisp. 20 THE COMMISSIONER: All right. 21 She will need to be sworn. Would you please 2.2 swear the witness. 23 FLORENCE CRISP, called as a witness, having been first duly 24 sworn, testified as follows: 25

1 THE COMMISSIONER: You may 2 proceed. 3 MR. WHITMER: Thank you. 4 DIRECT EXAMINATION 5 BY MR. WHITMER: 6 Ms. Crisp, what is your current 0. 7 position? 8 My name is Florence Crisp, and I'm Α. senior legal counsel for CVS Health 9 10 Corporation. 11 I'd like to start with a little bit of 0. 12 information about your education. Can you give 13 us a little background there? 14 I graduated from law school in 1998 Α. from Yale Law School. Following law school I 15 16 clerked for a federal court judge in the court 17 of appeals. Then I practiced at a New York law firm as an associate in the litigation 18 19 department. 20 When my family relocated to the Rhode Island area, I joined the law firm of 21 2.2 Edwards, Angell, Palmer & Dodge first as a 23 litigation associate and then as a partner. 24 And then in the summer of 2012 I joined CVS 25 Health in their legal department.

Page 18 Could you describe for us what your 0. role and responsibilities have been at CVS? Α. I have two primary areas of responsibility. One is around managing commercial litigation for the company and the other is around a variety of regulatory issues. That includes health care regulatory issues that impact our retail business. I also manage antitrust issues including regulatory filings when the company has significant transactions. We're here today to talk about CVS Q. Health and Aetna. I'd like to start with CVS Health. Could you give us a little bit of background information on the company? Α. CVS Health is a pharmacy innovation

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18 company that has been on a journey from being 19 known as a retailer to a health care company, 20 and we really think about our business in three 21 primary buckets.

The first bucket is those businesses where we provide care directly to patients. The second is Caremark, our pharmacy benefit manager. And then the third is the

1 insurance company that we currently own which 2 is SilverScript Insurance Company, which 3 provides Medicare Part D coverage, standalone 4 Part D coverage for Medicare enrollees. 5 I'd like to address each of those 0. 6 three categories that you just identified. 7 Let's start with your first category, "where we provide care." 8 9 Now, you've explained in your 10 affidavit -- we'll get to that in a minute --11 that there are five separate businesses 12 underneath this category of "where we provide 13 care." First is CVS Pharmacy. What can 14 you tell us about that? 15 16 So CVS Pharmacy is probably what we're Α. 17 most commonly recognized for. We have 9,800 18 pharmacies across the country where our 19 pharmacists not only dispense medication, but 20 also through face-to-face counseling and other 21 communications with patients address gaps in 2.2 care, improve medication adherence and 23 medication literacy and also help patients manage the cost of their drugs. 24 Second is the MinuteClinic. What is 25 0.

Page 20

1 that?

A. The MinuteClinic is a retail health
care clinic. We have approximately 1,100
across the country.

5 MinuteClinics provide acute 6 care for lower acuity conditions such as health 7 care screenings and minor illnesses. It's 8 really a supplement to primary care physicians. 9 Q. The third is CVS Specialty. Could you 10 explain that to us?

11 So CVS Specialty dispenses what I Α. 12 refer to as specialty medications. Those tend 13 to be very expensive or drugs that require a 14 higher touch, whether it be a cold chain or some other type of unique or atypical delivery 15 16 mechanism for patients who have more complex conditions. 17

18 Q. Fourth is Coram. Would you explain19 that to us.

A. Coram is a company that dispenses
infused medications, and most of these
interactions are actually home infusions, so
more convenient than the inpatient infusions.
Q. Fifth and finally is Omnicare. What
is that?

1	A. Omnicare provides pharmacy services to
2	long-term care facilities to address the needs
3	of the aging population.
4	Q. So let's move on now to the second
5	category, which is your pharmacy benefit
6	manager also known as a PBM, called CVS
7	Caremark.
8	Could you provide a little bit
9	of description for us?
10	A. Caremark provides the full range of
11	pharmacy benefit management services to its
12	clients, which includes employers, health plans
13	and government entities.
14	And that includes, you know,
15	development of formularies for the plans to
16	consider, prescription drug claim adjudication,
17	and a variety of different clinical programs to
18	help manage drug spend as well as keep the
19	members of those clients healthy.
20	Q. And then third and finally is the
21	category of our insurance, SilverScript.
22	What's that?
23	A. So as I mentioned before, SilverScript
24	is a standalone Part D drug plan. It's been
25	offering Part D coverage since that program was

Page 21

1 initiated back in the mid 2000s and provides 2 just the drug coverage to Medicare enrollees. Now that you've provided background 3 Q. 4 information on CVS, I'd like to talk more 5 specifically about this transaction we're here 6 today to discuss. 7 Could you provide just a brief description of the transaction? 8 9 Sure. Well, the companies entered Α. 10 into a merger agreement back in December of 11 2017. Pursuant to that agreement, the current 12 structure of Aetna, Incorporated, where you 13 have Aetna, Inc., is the public company and

14 then a variety of domestic insurers and 15 subsidiaries, including the two at issue here, 16 that structure will largely remain in place. 17 What will change is that rather 18 than public shareholders owning Aetna, Inc.,

18 than public shareholders owning Aetna, Inc., 19 CVS Pharmacy, Inc., will own Aetna, Inc., and 20 then CVS Pharmacy is owned by CVS Health, which 21 is a public company.

22 So the Aetna structure as it 23 exists will really be lifted and shifted over 24 into the CVS Health family of companies and 25 continue to operate largely as it does today.

1 So with respect to this transaction, 0. 2 could you just give us a few points about the 3 merger agreement it gave rise to? Sure. With the merger agreement CVS 4 Α. 5 Health will pay approximately 69 billion to the Aetna shareholders. The consideration is a 6 7 combination of cash and CVS stock that each shareholder will receive. 8 9 And when is the closing expected to 0. 10 take place? 11 The latter half of this year. Α. 12 I'd like to talk more specifically 0. 13 about your role and involvement in this 14 transaction. 15 Could you explain that to us? 16 Well, prior to the execution of the Α. 17 merger agreement, so approximately this time 18 last year I was involved in the due diligence 19 that led up to the signing of the merger 20 agreement. 21 Once it was signed, then my 2.2 role really shifted to the regulatory review 23 process at both the federal level with the 24 Hart-Scott-Rodino filing to the Department of Justice and then also the various Forms A that 25

Page 23

1 were filed across the country with respect --2 with various departments of insurance. And 3 since then have been involved in meetings with 4 regulators and responding to requests. 5 0. I'd like to now talk about the Form A 6 that has been submitted with respect to this 7 matter. 8 Could you tell us a little bit 9 about that?

10 A. Certainly. So the Form A, I believe, 11 was submitted on or about January 16th here in 12 Iowa and pertains to two domestic insurers that 13 are part of the Aetna family of companies.

Q. Okay. Now, that Form A is set forth in both of the exhibits that have been presented to the commissioner here today; is that your understanding?

18 A. That is.

19 Q. And before we come back and talk a 20 little bit more about that, I'd like to talk 21 about where we are currently at with respect to 22 other states around the country.

What can you tell us about that?
A. We have received -- so we've filed
Forms A or similar types of applications in

1 28 states.

2 We've received approvals from 3 20 of those states, and then we have 8 pending, 4 and that includes here, the pending review here 5 in Iowa. 6 Can you confirm for us that proper 0. notice has been given with respect to this 7 hearing today? 8 9 Yes. CVS Health received that notice Α. 10 and provided it to the domestic insurers. 11 Now, also on the two thumb drives that 0. 12 have been submitted to the commissioner are 13 copies of your affidavit in this matter. 14 You have a copy of that in front 15 of you have as well? 16 Α. I do. MR. WHITMER: I'd like to --17 18 Commissioner, if I could hand a copy to you as 19 well. 20 THE COMMISSIONER: Sure. 21 Ms. Crisp, what is the document Q. 2.2 sitting in front of you? 23 Α. This is the affidavit that I prepared 24 and signed in connection with the application. 25 0. Okay. And that is, in fact -- that

1 was your signature on the final page of the 2 affidavit? 3 Α. Yes, the one that you handed to the 4 commissioner. Okay. And has anything -- before you 5 0. 6 signed the affidavit, did you review it 7 carefully to confirm its accuracy? 8 Α. I did. 9 And has anything changed that would Ο. 10 require you to revise your affidavit from the 11 time it was signed until today? 12 Α. No. 13 Okay. That document has already been Q. 14 submitted into evidence, but I'd like to address some of the substance of that affidavit 15 16 here today. First of all, in preparing your 17 affidavit did you have the opportunity to 18 19 review the Iowa statute that we're here talking 20 about today? 21 Yes, I did. Α. 2.2 Okay. And specifically Iowa Code 0. 23 Section 521A.3(4)(a)(1-6)? 24 Α. Yes. 25 0. And did you have the opportunity to

1 evaluate how those six factors apply to the 2 transaction and whether, in fact, all six of 3 them were met? 4 Α. I did. 5 0. And you're prepared to testify today on all six of those factors? 6 7 Α. Yes, I am. Let's start with Requirement Number 1, 8 0. which considers whether the domestic insurers 9 10 will continue to satisfy the requirements for issuance of their licenses here in the state of 11 12 Towa. 13 First of all, let's identify, 14 we're here talking about two domestic insurers here today; is that right? 15 16 That's correct. Α. 17 Could you identify them for us? Q. Yes. It's Aetna Better Health of Iowa 18 Α. and Aetna Health of Iowa. 19 20 And can you establish for us that the Ο. 21 current licenses have been met with respect to 2.2 both of those domestic insurers? 23 Α. Yes. I reviewed documentation from 24 the department reflecting that those licenses 25 are currently in effect. They both hold HMO

1 licenses.

And do those licenses confirm that the 2 0. 3 domestic insurers currently satisfy the minimum 4 requirements for licensure in the state? 5 Α. Yes, they do. 6 And can you confirm for us that those 0. 7 licenses will remain intact post-transaction? 8 Yes, I can. First, CVS Health has no Α. 9 plans that would materially impact the domestic insurers' ability to continue to meet those 10 11 requirements for licensure. 12 And, second, CVS Health and 13 Aetna have very robust and proactive compliance 14 departments that will ensure that the domestic 15 insurers continue to meet quality assurance 16 standards and operate with high levels of 17 business integrity. Now, those issues are identified and 18 0. 19 discussed in your affidavit; is that correct? 20 Α. That's correct. 21 Based on what's in your affidavit and 0. 2.2 the information you provided here today for us, 23 can you confirm that Requirement 1 has been 24 met? 25 Yes, I can. Α.

Page 29

1	Q. Let's move forward then to
2	Requirement 2, which considers whether this
3	transaction will substantially lessen
4	competition in insurance in Iowa.
5	You reviewed that issue as well?
б	A. I did.
7	Q. First of all, I'd like to get a little
8	bit of background on the analysis that you
9	present in your affidavit on this issue.
10	Let's start with, where did you
11	get the information?
12	A. We obtained data from SNL Financial,
13	which obtains data directly from the NAIC.
14	Q. What company's data did you consider
15	for this analysis?
16	A. We looked at the data provided by
17	SNL Financial with respect to CVS Health and
18	its affiliates and Aetna and its affiliates.
19	Q. In evaluating that, how many total
20	lines of insurance did you evaluate?
21	A. So we identified five lines of
22	insurance where the CVS Health companies and
23	the Aetna companies report coverage or offer
24	coverage in Iowa to review.
25	Q. So just to be clear, how is it that

1 you identified those five and not any other 2 ones?

A. Well, there were other lines where Aetna offers coverage, but CVS does not hold a license to offer the coverage, and so therefore we did not review those because there was no overlap.

8 Q. Now, you also did not consider certain 9 other lines of business reported by Aetna. Why 10 is that?

11 A. Well, those are ones where CVS Health 12 does not hold a license to offer the coverage 13 and so there's no overlap.

14 So then let's talk about the five Ο. 15 lines that you evaluated in your analysis. 16 Let's talk, first of all, about four of them. Those four are Medicare 17 Title XVIII, other health, dental, and Title 18 XVIII Medicare. With respect to those four 19 20 lines, are there any competitive concerns? 21 There are no competitive concerns Α. 2.2 there because there would be no increase in the 23 share under any of those four because for each 24 of those four either CVS or Aetna reported 25 zero percent share.

Page 30

Q. And do those four lines qualify for a
 statutory exemption here?

A. Yes, they do.

Q. Let's move on to the fifth line. For that one, which is Medicare supplement located in the health only blank, is there any competition concern there?

8 A. There's no competition concern. Both 9 companies do report some premiums, but they're 10 very, very small.

11 CVS reports, I believe, 26,000 12 in premium and Aetna approximately 14,000. 13 So the increase is, I believe, .01 percent 14 increase, so a very tiny increase which, based 15 on my understanding, would be entitled to an 16 exemption.

Q. The statutory exemption here in Iowa?A. Statutory exemption, yes.

Q. You addressed the five lines, but I'd
also like to give you an opportunity to talk a
little bit about Medicare Part D.

A. Yes. So both companies currently do offer Medicare Part D coverage, and while we did not believe that there was a competitive concern there, Aetna has entered into an agreement to sell its standalone Part D
 business to WellCare.

3 This is documented in a consent 4 order that the parties have agreed to with the 5 Department of Justice. And, therefore, to the 6 extent that there were any concerns with 7 respect to the overlap in the Medicare Part D context, those concerns are addressed by the 8 9 divestiture by Aetna of its Part D business. 10 So there are no competition concerns Ο. 11 on Part D either? 12 Α. No. 13 Q. Having addressed the five lines and 14 Medicare Part D, can you confirm for us that 15 there are no concerns with respect to Factor 16 Number 2?

17 A. Yes, I can.

18 Let's move forward then to Requirement 0. 19 This considers the financial Number 3. 20 condition of the applicant and whether it will 21 jeopardize the financial stability of the 2.2 domestic insurers or prejudice the interests of 23 the domestic insurers' policyholders. 24 With respect to that factor, 25 what can you tell us first about CVS Health's

1 financial strength?

2 CVS is financially very sound. Α. Τn 3 2017 we reported net revenues of 185 billion and net income of 6.6 billion. 4 Now, there will be a certain amount of 5 0. 6 debt with respect to this transaction; correct? 7 That is correct. Α. 8 Can you explain to us who is going to 0. 9 bear that debt? 10 That debt is the obligation of CVS Α. Health at the parent level. It is not the 11 12 obligation of any domestic insurer, and no 13 domestic insurer is obligated with respect to 14 the paydown of that debt. 15 0. I'd like to now ask you a little bit 16 about the financial strength of the two domestic insurers that you've been talking 17 18 about. 19 What can you tell us about them? 20 They are also financially sound. Α. 21 Aetna Health of Iowa reported capital and 2.2 surplus of 38.5 million in its last report. 23 And Aetna Better Health reported a capital and 24 surplus of 1.1 million. Based on that information and the 25 0.

1 additional facts that you set forth in your 2 affidavit, can you confirm for us that that 3 requirement, Number 3, has also been satisfied? 4 Α. Yes, I can. 5 0. Let's move forward then to 6 Requirement 4. This considers whether the 7 applicants have any plans or proposals with regard to the domestic insurers that are unfair 8 or unreasonable to the domestic insurers' 9 10 policyholders or that are not in the public 11 interest. 12 First of all, can you confirm 13 for us that the applicants have no plans to 14 cause the domestic insurers to declare any extraordinary dividends? 15 16 Α. I can. 17 Q. And also that the applicants have no plans to liquidate the domestic insurers? 18 That's correct. 19 Α. 20 Also they have no plans to make any Ο. material change to the domestic insurers' 21 2.2 business? 23 That is correct. Α. 24 0. Tell us a little bit about why you 25 believe this requirement has been met here.

1 Well, not only do we believe that this Α. 2 is, you know, not something that would 3 prejudice, but we think by combining the 4 financial strength of CVS as well as the 5 innovative ideas of bringing these two companies together, it is really something that 6 7 is in the interest of the insurance-buying population. 8

9 Q. Will the domestic insurers continue 10 post-transaction to maintain their separate 11 corporate existences?

12 A. They will.

Q. Tell us, will there be any material
changes in the board of directors or senior
management for either of the domestic insurers?
A. There will not be any changes at the
domestic insurer level. The only changes that
would be made is if individuals chose to resign

19 following the close of the transaction.

20 Q. As we are considering Requirement 4, 21 I'd like to give you an opportunity to identify 22 any benefits that you would see with respect to 23 the combined organization. I'd like to have 24 you address four of them. They're in your 25 affidavit. I'd like to give you a chance to 1 address each of them.

2 First of all, you said there's 3 the improvement of the quality and coordination 4 of care. Can you explain that? 5 Α. I think one of the key values that we 6 see of this transaction is really bringing together the pharmacy data and pharmacy profile 7 of patients with their medical profile and 8 their medical claims. 9 10 Currently those two bodies of 11 information about patients are not as fully 12 integrated as we feel they should be, and we 13 feel by bringing them together we're going to 14 be able to provide a much better coordination of care and have a holistic view of the patient 15 16 that we then will be able to ensure that all 17 providers can see when they're coming up with a 18 care plan for their patient. 19 Second, you've explained that this 0. 20 transaction will result in lower costs, 21 clinically tailored and more convenient sites. 2.2 Could you explain that? 23 Well, I think one of the keys we see Α. 24 here is that, you know, trying to shift the

health care system from one that is focused on

25
patients when they're broken to one that focuses on keeping them healthy, and a lot of that is trying to find more convenient ways for patients to access care before they've reached an acute episode.

And so by helping identify opportunities to shift sites of care to sites that are more convenient and, frankly, less expensive, we think they'll be a great benefit to patients.

Q. Third, you explained that this transaction should improve the continuity of care. Would you explain that?

14 Again, this goes back to that Α. integration of the data, of pharmacy data and 15 16 medical data in order to ensure that over the 17 lifetime of the patient that information is 18 seen holistically and we can identify risk 19 points using that data more effectively. 20 Aetna's got very robust 21 analytics capabilities, and this will 2.2 supplement the effectiveness of those 23 capabilities to identify, you know, risk points 24 in a patient's life where interventions could 25 be effective at keeping the patient healthy or

1 helping them when they do face a critical point 2 in their health care. 3 Q. Fourth and finally, you explain in your affidavit that this transaction is 4 5 expected to contain costs. 6 What does that mean? 7 We really see that on two fronts. One Α. is, you know, we do believe that as a result of 8 the transaction we'll be able to lower certain 9 10 costs and realize approximately 750 million in 11 cost savings after the end of the second year 12 post-transaction, and that will be annual. 13 But, more importantly, we do 14 think that by focusing on delivering more convenient and less expensive care to patients 15 16 that patients will see a reduction in their own 17 costs. 18

18 Rather than paying a co-pay for 19 an emergency room visit, it may be getting that 20 patient into a lower cost site of care earlier 21 to avoid the acute situation that might lead 22 them to the emergency room.

Q. And then lastly, could you tell us a little bit about the transaction negotiations that gave rise to this deal?

Page 38

Certainly. Very robust negotiations. 1 Α. Both sides had retained a number of external 2 3 advisors, both law firms and financial 4 advisors, and a lot of back and forth of arm's 5 length negotiations with respect to the merger 6 agreement that was entered into. What can you tell us about any 7 Q. stockholder or board votes? 8 9 So the merger agreement obviously was Α. 10 conditioned on approval by both boards of directors. Both boards of directors voted 11 12 unanimously to approve the transaction. 13 It was also conditioned on 14 shareholder approval. There was overwhelming approval. I believe on the Aetna side 15 16 97 percent of the shareholders who were voting 17 voted to approve it. On the CVS side the 18 19 shareholders were voting to issue the 20 additional stock necessary, and 98 percent of the shareholders who voted voted in favor of 21 2.2 issuing that stock. 23 So based on those facts and the 0. 24 information that you provide in your affidavit,

25 can you confirm for us that Requirement 4 has

2 A. Yes, I can.
3 Q. Let's jump forward then to

been met with respect to this transaction?

1

4 Requirement 5. This considers the competence, 5 experience, and integrity of those who will 6 control the domestic insurers post-transaction. 7 Let's start with talking about, 8 who will the makeup be of the new board of 9 directors?

10 A. So this is speaking with respect to 11 CVS Health Corporation, the ultimate parent 12 company. We currently have a board of 13 directors of twelve members.

14 That's going to be expanded 15 upon the close to add four additional seats, 16 and those seats will be occupied by the current 17 Aetna CEO and chairman, Mark Bertolini, and 18 then three other Aetna board members, 19 Mr. Farah, Mr. Ludwig, and Mr. Aquirre. 20 And is there any other changes that Ο. 21 you want to talk about with respect to 2.2 Ms. Lynch, Mr. Denton, or anyone else? 23 Yes. With respect to the senior or Α. 24 the executive officers of CVS Health, Karen 25 Lynch, who is currently the president of Aetna,

Inc., will remain in that role and she'll lead
 the Aetna business unit reporting directly to
 our CEO.

And the other changes that will be happening at the close, our current CFO is resigning, and Eva Boratto will take that role. And then James Clark will step into the role of controller and chief accounting officer.

9 I'd like to talk more specifically Ο. about certain of these individuals, and let's 10 11 start with the current directors of CVS Health, 12 and there are twelve of them. Mr. Bracken, 13 Mr. Brown, Ms. DeCoudreaux, Ms. De Parle, Mr. Dorman, Ms. Finucane, Mr. Merlo, 14 Mr. Millon, Ms. Schapiro, Mr. Swift, 15 16 Mr. Weldon, and Mr. White. 17 First of all, what's your 18 familiarity with respect to those twelve individuals? 19

A. With some of them I've worked
extensively with them. With others I've
reviewed their biographical -- well, with all
I've reviewed their biographical affidavits
that were submitted with the application.
Q. And based on your knowledge of working

with certain of these individuals and reviewing 1 2 the affidavits of all of them, what can you 3 tell us about their competence, experience, and 4 integrity? 5 Α. These are individuals of, you know, 6 very high degrees of competence. They have substantial experience, years and years, and 7 8 have operated with very high levels of 9 integrity. 10 0. Shifting over now to the executive officers of CVS Health, there are nine of them. 11 12 All of them are addressed in your affidavit, 13 but I want to give you an opportunity to 14 address them briefly here.

15 Mr. Merlo, Mr. Denton,

Mr. Moriarty, Ms. McIntosh, Mr. Roberts, Doctor 16

17 Brennan, Ms. Boratto, Derica Rice, and

18 Mr. Hourican.

19 What's your familiarity with 20 those nine executive officers?

21 I've had the opportunity to work with Α. 2.2 all of them extensively, and I've also reviewed 23 their biographical affidavits.

24 0. And based on that information and that 25 review, what can you tell us about these nine

1 individuals?

2	A. They are also individuals of
3	substantial experience, very competent, and who
4	have operated at high levels of integrity.
5	Q. Moving over now to CVS Pharmacy, there
6	are two individuals that serve both as the
7	directors and the executive officers,
8	Ms. DeNale and Mr. Moffatt.
9	What can you tell us about those
10	two individuals?
11	A. I've worked extensively with both of
12	them as well and have reviewed their
13	affidavits, and based on that review as well as
14	my experience working with them, I can
15	certainly attest that they have high degrees
16	of they operate with high degrees of
17	integrity, they have extensive experience, and
18	are extremely competent.
19	Q. Now moving over to discuss the
20	domestic insurers, first of all, let's talk
21	about Aetna Better Health of Iowa, Inc.
22	There are three directors, okay, Ms. Bacon,
23	Ms. Brubaker, and Ms. Grant.
24	What do you know about those
25	three?

1 I have reviewed their affidavits. Α. 2 Having done so, what can you tell us? 0. 3 They certainly have a record of Α. 4 operating with high levels of integrity, 5 substantial years of experience, and extremely 6 competent in their roles. Okay. The seven executive officers of 7 Q. Aetna Better Health of Iowa, they're in your 8 affidavit. Ms. Brubaker, Mr. Maroney, 9 10 Mr. Kessler, Ms. Bacon, Mr. Chronister, Mr. Casey, and Mr. Olson. 11 12 What can you tell us about those 13 seven? Again, I've reviewed their affidavits, 14 Α. and based on that review it's clear that they 15 16 are individuals with high levels of competence who have substantial experience and who operate 17 18 with high levels of integrity. And then, finally, with respect to 19 0. 20 Aetna Health of Iowa, there are three 21 directors, Mr. Christensen, Mr. D'Antonio, and 2.2 Mr. Sloma. 23 Have you reviewed the 24 biographical affidavits for those individuals, 25 and if so, what can you tell us?

1 Yes, I did. From that review, it's Α. 2 clear that they also have significant expertise 3 and experience, they operate with high levels of integrity, and are very competent. 4 5 0. And then, lastly, with respect to the executive officers of Aetna Health of Iowa, 6 7 theres six of them. Mr. D'Antonio, 8 Mr. Maroney, Mr. Lee, Mr. Reinecke, Mr. Casey, 9 and Mr. Chronister. 10 What can you tell us about them? 11 I've reviewed their biographical Α. 12 affidavits, had the opportunity to work with at 13 least Mr. Lee on that list, and based on my 14 interactions as well as my review of the affidavits, it's clear that they are very 15 16 competent, have substantial experience, and 17 operate with high levels of integrity. Based on that information, can you 18 0. confirm for us that Requirement 5 is met here? 19 20 Α. Yes, I can. 21 Then, finally, let's talk about 0. 2.2 Requirement 6, the last requirement. And this 23 considers whether the transaction is likely to 24 be hazardous or prejudicial to the 25 insurance-buying public.

Page 45

Page	46
------	----

1	Has that requirement been met
2	here? And if so, can you explain why?
3	A. Yes, I think based on all of the
4	information that I've talked about already,
5	which is detailed in more detail in my
6	affidavit, we firmly believe that this is not
7	hazardous, but instead in the interest of the
8	insurance-buying public.
9	And I think the only additional
10	thing I would note is that CVS Health has a
11	long record of successful integration of new
12	companies, and so we are looking forward to
13	continuing that record with this transaction
14	here.
15	Q. So based on that information and
16	what's set forth in your affidavit, has
17	Requirement 6 been met?
18	A. Yes, it has.
19	Q. Before you complete your testimony
20	here today, are there any final comments that
21	you would like to provide to the commissioner
22	or to the department with respect to this
23	transaction?
24	A. Well, I'd just like to take an
25	opportunity to thank the department, thank the

1 commissioner. I know this is a hefty 2 application, and we really appreciate the time 3 and resources that went into reviewing it. 4 We are very excited about this 5 We do believe it has the transaction. 6 potential to transform health care. We think 7 health care needs transformation and needs innovation, and we think that this is the best 8 path forward there. 9 10 So with that, we respectfully 11 request that you approve the application. 12 MR. WHITMER: Thank you, 13 Ms. Crisp. 14 Commissioner, I have no further questions, but I want to make the witness 15 16 available to you or to your team that would 17 like to ask any questions of her. 18 THE COMMISSIONER: Thank you, 19 Ms. Crisp, for your testimony. Are there any questions from the division? 20 21 MR. ARMSTRONG: Yes, there is. 2.2 THE COMMISSIONER: Please 23 proceed. 24 MR. ARMSTRONG: Ms. Crisp, how does CVS plan to repay the debt without passing 25

1 the cost along to the Iowa policyholders? 2 MS. CRISP: I would be happy to 3 address that. So -- and we provided this 4 information to the rating agencies and others. 5 CVS Health currently generates 6 substantial cash flow that we currently use 7 either to buy back shares in the market or to increase our shareholder dividend. 8 9 We have announced that we are 10 going to suspend share repurchases, and that 11 was typically in the 5 to \$6 billion a year 12 range for CVS. 13 So we're going to suspend share 14 repurchases and suspend any shareholder dividend increases for our public shareholders 15 16 until we have returned to an adjusted debt --17 to an adjusted ratio of the mid 3's, three 18 times, which is in line with where we have been 19 historically. 20 MR. ARMSTRONG: Okay. And 21 none of the cost of that or interest payments 2.2 on the debt will be passed along to Iowa 23 policyholders? 24 MS. CRISP: No. 25 MR. ARMSTRONG: Okay. If this

1 transaction is approved, CVS will be regulated 2 as an insurance holding company here in Iowa. 3 Does CVS understand that and 4 will it cooperate with the Iowa regulators? 5 MS. CRISP: Yes. б MR. ARMSTRONG: Okay, thank you. 7 And my last question, are there any contracts to this transaction that we have not been made 8 9 aware of? 10 MS. CRISP: No. 11 MR. ARMSTRONG: Okay. 12 MR. HUNTER: Just a few 13 questions. 14 THE COMMISSIONER: Go ahead. 15 CROSS-EXAMINATION 16 BY MR. HUNTER: 17 Q. Did you assist in the preparation of the Form A statement that was filed with the 18 19 department? 20 Α. Yes, I did. 21 And were you familiar with the 0. 2.2 application and its contents thereof when it 23 was submitted? 24 Α. Yes. And are the facts contained in the 25 0.

Form A statement true to the best of your
 knowledge, information, and belief?

3 A. Yes.

Q. Do the statements contained in the
application as amended, restated, and
supplemented remain true today, to the best of
your knowledge?

8 A. Yes.

9 When the application filed -- when the 0. 10 applicant filed the Form A statement that is 11 subject to today's proceedings, did you ensure 12 that you had become aware of any facts, acts, 13 or circumstances that could impact the 14 statements made therein? 15 Α. Yes.

16 Q. Are there any material facts omitted 17 from the Form A as amended, restated, or 18 supplemented that you'd like to add?

19 A. No.

20 Q. Are there any misleading statements 21 in the Form A as amended, restated, and 22 supplemented?

23 A. No.

Q. Have there been any material changesto the facts, statements, or representations in

the Form A since the most recent amendment or restatement? Α. No. MR. HUNTER: That's all. MS. CROSS: I have one additional question. THE COMMISSIONER: Yes. MS. CROSS: You had mentioned in your testimony that the Form A was submitted on January 16 of 2018; correct? MS. CRISP: That's -- it was on or about. I know that that's --MS. CROSS: Correct. And Mr. Hunter was referencing subsequent amended, restated, and/or supplemented. MS. CRISP: Yes. MS. CROSS: Can you provide some additional clarity as to when that was last amended, restated --MS. CRISP: I believe --

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

MS. CRISP: Yes. I believe it
was October 18th.
MS. CROSS: Approximately.

MS. CROSS: -- or supplemented?

25 MS. CRISP: It was within the

Page 52

1 last week or so, is what I could say. 2 MS. CROSS: Understood. 3 MS. CRISP: I don't recall the 4 precise date, but I believe Mr. Farber can 5 provide that momentarily. 6 MR. FARBER: Yeah. I think the 7 latest --8 MS. CRISP: Oh, I believe it was I've got it in my affidavit. 9 the 19th. 10 MR. FARBER: I believe the 22nd. 11 MS. CROSS: I just wanted to 12 clarify for the record. 13 MS. CRISP: I appreciate that, 14 yes. My responses were based on the amended 15 and restated version, yes. 16 Ms. Crisp, THE COMMISSIONER: 17 you mentioned earlier about the increase in efficiencies associated with this change and I 18 19 heard you testify about the need for 20 transformation in the delivery of health care, 21 and I certainly understand and appreciate all 2.2 of that. 23 We also regulate Caremark, which is the PBM, and so one of my questions 24 25 really relates to, how do you see this merger

impacting that part of the business, or how is it that you've made efforts to really sort of address some concerns that may be out there in the industry in that part of the business of health care?

6 MS. CRISP: Well, I think 7 largely, you know, we've been in a long-term relationship, PBM relationship with Aetna and 8 9 so things, I think, will not -- there will not be change in terms of -- we'll continue to 10 11 service Aetna as its PBM and continue to work 12 with Aetna to provide, you know, the services 13 to Aetna's clients with respect to prescription 14 drug coverage as well.

15 We do think there's an 16 opportunity for greater integration of the 17 pharmacy data and the medical data and are 18 looking forward to exploring how best to, you 19 know, integrate that. We are not gun-jumping 20 now, so, you know, what those plans will look 21 like will really come to fruition after the 2.2 close, but we are excited to explore those 23 opportunities.

THE COMMISSIONER: And, again,
this may be far afield from today's proceeding,

1 but, I mean, do you see the PBM business at 2 Caremark changing, you know, in terms of -- not 3 just in terms of this trans -- basically this merger, but just beyond that? 4 MS. CRISP: You know, I think 5 6 we're always trying to evolve to meet the needs 7 of our clients, and we service, you know, health plans, employers, as well as government 8 entities, so we'll continue to work with our 9 10 clients to address the rising health care 11 costs. 12 Our business has evolved over 13 time. You know, I think one example is we were 14 one of the first to start offering a plan for our clients where they could give rebates to 15 16 their members at the point of sale, and so we 17 will continue to evolve products in the market to address the desires and concerns of our 18 19 clients. 20 THE COMMISSIONER: And the last 21 question I have with regards to the Department 2.2 of Justice. And I heard you describe that 23 there is a settlement that is awaiting court 24 approval. Do you have any idea as to the 25 timing of that final approval?

Page	55
------	----

1	MS. CRISP: We expect it to
2	be and I will say I'm not the expert on the
3	mechanics of all this, but we expect it to be
4	pretty straightforward based on both the
5	Department of Justice and CVS and Aetna
6	submitted this as, you know, a consent order,
7	so we expect it to come shortly.
8	THE COMMISSIONER: I also saw in
9	your affidavit a reference to state attorneys
10	general, and what
11	MS. CRISP: Several state
12	attorneys general did join that consent order,
13	yes.
14	THE COMMISSIONER: All right.
15	So I guess in regards to that question, are
16	there any outside procedural issues associated
17	with state AG involvement, or is it all wrapped
18	into the Department of Justice review?
19	MS. CRISP: It's all wrapped
20	into the review.
21	THE COMMISSIONER: Thank you. I
22	have no further questions.
23	MS. CRISP: Thank you.
24	MS. CROSS: I have one
25	additional question, if I may.

|--|

1 You indicated that you're in the 2 process of divesting the Medicare Part D 3 business to WellCare. 4 Do you have a sense of when that 5 divestiture will be complete? 6 MS. CRISP: Well, so Aetna is 7 selling its business to WellCare. 8 MS. CROSS: Right. 9 MS. CRISP: That divestiture is conditioned on the closing of this transaction. 10 MS. CROSS: Okay. 11 12 MS. CRISP: In order to minimize 13 any impact on members, if that transaction 14 moves forward, Aetna will service those members through a transition services agreement through 15 16 the next plan year. 17 Medicaid is on, you know, an 18 annual cycle with annual enrollment in the fall 19 and then the plan year starting in January. And so they'll continue to service the plan 20 21 members throughout the 2019 plan year. 2.2 THE COMMISSIONER: Any further 23 questions of this witness? Seeing none, thank you, 24 25 Ms. Crisp --

1	MS. CRISP: Thank you.
2	THE COMMISSIONER: for your
3	testimony. And you may call your next witness.
4	MR. WHITMER: Thank you,
5	Commissioner. Our second and final witness
б	we're calling is Gregory Martino. I guess he
7	can be sworn in at this time.
8	THE COMMISSIONER: He will need
9	to be sworn.
10	GREGORY MARTINO,
11	called as a witness, having been first duly
12	sworn, testified as follows:
13	DIRECT EXAMINATION
14	BY MR. WHITMER:
15	Q. Mr. Martino, could you state your full
16	name for the record?
17	A. My name is Gregory Martino.
18	Q. And what is your current title with
19	Aetna?
20	A. I work for Aetna, Inc., and I'm
21	currently assistant vice president for state
22	government relations.
23	Q. What are your responsibilities at
24	Aetna in that role?
25	A. My responsibilities at Aetna really

Page 58

1 are engaged in regulatory matters, some 2 legislative matters, but primarily regulatory 3 matters dealing with insurance departments 4 across the country, dealing with regulatory 5 approval, a number of different matters, 6 including mergers and acquisitions. 7 I've been involved in both the 8 Coventry and Humana acquisitions that were 9 proposed and completed. And obviously now I 10 have the pleasure of working on the CVS 11 transaction. 12 Let's talk a bit about your industry 0. 13 roles before you came to your role at Aetna. 14 What can you tell us about that? 15 Α. Prior to joining Aetna in 2000, 16 approximately 2000, I actually served with the 17 Pennsylvania Insurance Department for a number 18 of years in a number of different capacities. 19 I served as deputy insurance 20 commissioner for company regulation, which 21 deals with rates and forms and dealing with the 2.2 overseeing of the market there. 23 I also was deputy insurance 24 commissioner for consumer services and market 25 conduct and also had the pleasure of serving as

1 the acting insurance commissioner in

2 Pennsylvania for six months.

3 0. Let's talk about this transaction. 4 What has your role been here? I've been involved in this just prior 5 Α. 6 to the transaction being publicly announced on 7 December 3rd. Since that time, since December 3rd, the public announcement, 8 virtually all of my time has been spent on the 9 10 transaction. 11 I've been engaged in working 12 with CVS on preparing the Form A's, been engaged with CVS in regulatory outreach and 13 14 education to commissioners and staff, through 15 insurance departments across the country 16 regarding this transaction. 17 I also have worked on the 18 hearings that have occurred to date, and I've testified in a number of those hearings. 19 20 We've heard some background 0. 21 information on CVS. Why don't you take this 2.2 opportunity to give some background information 23 on Aetna. 24 Α. Sure. Aetna, as you know, is a large

25 national insurance company. It really is a

diversified company providing health care benefits serving approximately 46 million members, with the ultimate goal of helping members achieve better health and providing them with the information and resources to provide a better health care system.

Q. Now, we've already heard a little bit from Ms. Crisp about the two domestic insurers here, but I'd like to give you an opportunity to talk about it as well.

11 Let's start with Aetna Better 12 Health of Iowa. What can you tell us? 13 Α. Aetna Better Health of Iowa is an HMO 14 licensed in the state of Iowa. It was licensed in April of 2015. Currently it has no 15 16 membership on it, but it is, in fact, being 17 held and the license is being maintained for 18 future opportunities.

19 Q. What about Aetna Health of Iowa, Inc., 20 what can you tell us about that domestic 21 insurer?

A. Aetna Health of Iowa has been around for a number of years. It was licensed in 1985, I believe February of 1985, and has been an HMO operating in the state of Iowa with

1 approximately 44,000 members. 2 Sir, you also prepared an affidavit Ο. 3 with respect to this matter; is that right? 4 Α. Yes, I did. Is that your affidavit right there? 5 0. Yes, it is. 6 Α. 7 Okay. If you turn to the last page, Q. just confirm for us, is that, in fact, your 8 9 signature? 10 Α. Yes, it is. 11 Okay. And before you signed the Q. 12 affidavit, did you carefully review it to make 13 sure that all the information contained therein 14 was true and accurate? 15 Α. Yes, I did. 16 And has anything changed since the 0. 17 time you signed that affidavit which would 18 require you to modify it in any way as we sit here today? 19 20 Α. No. 21 Commissioner, I MR. WHITMER: 2.2 would ask for the opportunity to hand up a copy 23 of Mr. Martino's affidavit. 24 THE COMMISSIONER: Thank you. And I assume this is also found in both the 25

Page 61

1 confidential and public Form A document that 2 previously was received? 3 MR. WHITMER: It is. 4 THE COMMISSIONER: All right. 5 MR. WHITMER: It is on both of 6 the thumb drives. 7 THE COMMISSIONER: All right. 8 Thank you. 9 Mr. Martino, you've also taken the 0. 10 opportunity, as set forth in your affidavit, to address certain of the six factors that 11 12 Ms. Crisp discussed here today; is that right? 13 Α. Yes. I'm not going to have you address all 14 0. of them, but I want to give you the opportunity 15 16 to address some of them. 17 Let's start with Requirement Number 1, which talks about whether the 18 19 domestic insurers will continue to satisfy 20 licensure requirements in the state. 21 First of all, have both -- do 2.2 both of the domestic insurers currently have 23 appropriate licensure? Yes, they do. I've reviewed various 24 Α. 25 documentation that demonstrates that they

1 currently are licensed, both entities are 2 licensed in the state of Iowa as HMOs. 3 Q. And can you confirm for us that post-transaction both of the entities will 4 continue to have appropriate licenses here in 5 6 the state of Iowa? 7 Yes, I believe they will continue to Α. meet the requirements to hold those licenses. 8 9 Based on your testimony and the Ο. 10 testimony of Ms. Crisp, can you confirm that 11 Requirement 1 has been met here? 12 Yes, I can. Α. 13 With respect to Requirement 2, that's 0. 14 already been addressed by Ms. Crisp and her submission, so we're going to skip 2 and move 15 16 to 3. 17 Requirement 3 considers the financial condition of the applicant and 18 whether it will jeopardize the financial 19 20 stability of these two domestic insurers we've 21 been discussing. 2.2 What can you tell us about the 23 domestic insurers' financial strength? 24 Α. Certainly. Well, Ms. Crisp addressed 25 the large holding company of CVS. I will

comment on the two HMOs licensed in Iowa.
 Both Aetna Better Health and
 Aetna Health, Inc., are very well financially
 sound with capital and surplus, Aetna Better
 Health having approximately \$1.1 million and
 Aetna Health of Iowa having approximately
 \$38.5 million.

8 Q. And based on the information you 9 provided both in your affidavit and here today 10 and what Ms. Crisp has provided, can you 11 confirm for us that that third requirement has 12 been met?

13 A. Yes, I can.

Q. Jumping forward then to Requirement 4, it considers whether the applicants have any plans or proposals with respect to the domestic insurers that are unfair or unreasonable.

18 Can you tell us your expectation 19 or understanding with respect to the domestic 20 insurer businesses post-transaction?

A. Post-transaction I believe they will
continue to meet the statutory requirements,
they will not have any issues and concerns.
I am not aware of any plans to
change the operations, the management, the

1 senior team of those individuals, except for 2 those individuals replaced through resignation. 3 Q. Can you tell us just a bit about the 4 transaction negotiations from Aetna's 5 perspective? 6 Α. Certainly. Transactions were 7 negotiated at arm's length. We, Aetna had hired independent and separate financial 8 advisors to review the documentation and review 9 10 all the paperwork. 11 In addition to that, we had 12 separate lawyers, independent lawyers prepare 13 and review all the documentation also. 14 And what can you tell us about any 0. board of directors or shareholder votes? 15 16 Α. The board of directors for Aetna did 17 approve, unanimously approve the transaction. In addition to that, the shareholders 18 overwhelmingly approved with over 97 percent 19 20 approving the transaction. 21 Sir, can you confirm for us based on 0. 2.2 your information and what you've heard here 23 today that Requirement 4 has been met? 24 Α. Yes, I can. 25 0. Let's jump forward to Requirement 5.

First of all, let's talk about the competence,
 experience, and integrity of the domestic
 insurers.

4 Let's start with Aetna Better 5 Health of Iowa. You've already heard about 6 three of the individuals who are the directors, 7 Ms. Bacon, Ms. Brubaker, and Ms. Grant. What do you know about those 8 9 individuals and what can you tell us? 10 I've had the pleasure of working with Α. them over and over a number of years and also 11 12 reviewed their biographical affidavits and can 13 tell you that those are individuals of high 14 competence, many, many years of experience, and 15 they have very strong, strong integrity. 16 What's your knowledge of the seven Ο. 17 executive officers of Aetna Better Health of 18 Iowa? Again, Ms. Brubaker, Mr. Maroney, 19 Mr. Kessler, Ms. Bacon, Mr. Chronister, 20 Mr. Casey, and Mr. Olson. 21 Do you know those individuals? 2.2 I know those individuals also. Α. T have 23 had years of working with them. I have also 24 reviewed the biographical affidavits for each 25 of those, and I can tell you all of those

1 individuals are also individuals of high 2 integrity, strong, many years of experience and 3 also have highly competent backgrounds. 4 0. And jumping over to the other domestic 5 insurer, Aetna Health of Iowa, there are three 6 directors, Mr. Christensen, Mr. D'Antonio, and 7 Mr. Sloma. 8 Do you know those three 9 individuals? 10 Yes, I do. I also have had the Α. pleasure of working with them over the years 11 12 and have reviewed their biographic affidavits. 13 Q. What can you tell us about them? 14 Again, those are individuals that are Α. 15 highly competent, years of experience, strong experience, positive experience, and also have 16 17 very strong integrity. And then, finally, let's talk about 18 0. the executive officers of Aetna Health of Iowa. 19 There are six of them. Mr. D'Antonio, 20 Mr. Maroney, Mr. Lee, Mr. Reinecke, Mr. Casey, 21 2.2 and Mr. Chronister. 23 What do you know about those six 24 individuals and what can you tell us about 25 them?

Page	68
------	----

1 Sure. I'd continue to say that I've Α. 2 worked with all of those and have also reviewed 3 their biographical affidavits. 4 Based on my years of experience working with them and reviewing the 5 6 biographical affidavits, these are individuals 7 of high competency, years of experience, and high integrity. 8 9 So you can confirm for us that Ο. 10 Requirement 5 has been met here? 11 Yes, I can. Α. 12 Then, finally, Requirement 6, again 0. 13 considering whether the transaction is likely 14 to be hazardous or prejudicial to the insurance-buying public. 15 16 Has that requirement been met, 17 and if so, why? 18 Yes, it has been met. My affidavit Α. discusses a lot of this. 19 I really would just 20 say that Aetna for years has been trying to 21 transform the health care system and health 2.2 care. 23 And one of the areas that we 24 really recognize as critical in all of this is really community based, being involved in the 25

community, getting health care as local as
 possible.

The significant advantage we see here is partnering up and being acquired by CVS will provide us with that opportunity while Aetna has significant data and the analytics to do the analysis of health care, having that local, local presence will be significant as part of it.

10 Q. So Requirement 6 has been met here?11 A. Yes, it has.

Q. Before you complete your direct examination, is there anything you'd like to share with the commission or the department with respect to the transaction?

A. I'd like to thank the commissioner for the time he's taken on this matter and more importantly, as important, the staff who's reviewed through those pounds and pounds of paper to review the Form A transaction and has gone through that.

22 We appreciate that very much. 23 We recognize the burden that it causes and the 24 work that it causes the department.

25 And I also think this is going

1 to be a great opportunity. It's really a great 2 opportunity for the enrollees here and the 3 future enrollees in Iowa. 4 As health care is being 5 transformed and we really begin to look and 6 focus on a localized delivery system with 7 Aetna, I think it will be a huge improvement for folks. 8 Thank you. 9 MR. WHITMER: Thank you, 10 Mr. Martino. 11 Commissioner, I want to turn it 12 back to you and the department for any 13 questions you may have. 14 THE COMMISSIONER: Thank you, 15 Mr. Whitmer. Do you have any questions? 16 MR. ARMSTRONG: Just one. Are 17 there any contracts to this transaction that we have not been made aware of? 18 19 MR. MARTINO: No, I'm not aware 20 of any. 21 MR. ARMSTRONG: Okay. Thank 2.2 you. 23 MR. HUNTER: No questions. 24 THE COMMISSIONER: Any questions 25 from anyone else who has appeared today?

Page	71
------	----

1	Seeing none, I have no
2	questions. Thank you, Mr. Whitmer, and
3	Mr. Martino for your testimony.
4	Any further witnesses?
5	MR. WHITMER: We have no further
6	witnesses. I will turn it back to you.
7	THE COMMISSIONER: All right,
8	thank you. Is there any other evidence to be
9	offered with regards to the parties that are
10	party to the transaction?
11	MR. WHITMER: Nothing further
12	from CVS. Mr. Krane?
13	MR. KRANE: Nothing further from
14	Aetna.
15	THE COMMISSIONER: Thank you
16	very much. All right. At this time I'll take
17	any public comments that may be offered. So is
18	there anyone in attendance that wishes to offer
19	additional testimony for consideration with
20	regards to this acquisition?
21	Seeing none, I have received a
22	letter from UnityPoint Health signed and
23	received on excuse me dated August the
24	30th and received on September the 10th of
25	2018.

1	I would like that marked as an
2	exhibit and received as evidence. I would be
3	happy to offer that for anyone's review if
4	you'd like. I'm not going to read it into the
5	record. It's a one-page letter and is
6	favorable for the acquisition.
7	I do want to give you at least
8	the opportunity to review it should you have
9	any additional comments with regard to that
10	comment.
11	MR. WHITMER: No objection.
12	Thank you.
13	(Exhibit C was marked for
14	identification by the reporter.)
15	THE COMMISSIONER: All right.
16	I'll make one last call for any public comment
17	or for any other interested party that may be
18	in attendance.
19	All right. With that and the
20	evidence that has been received, it is
21	voluminous, so it will give me plenty of
22	reading opportunity over the next couple of
23	days, but I will go ahead and close the record
24	at this point.
25	It depends, of course, on the
information that's been received in terms of 1 2 timing, but I do intend to move forward fairly 3 expeditiously in my decision-making. 4 I do have a little bit of a 5 question with regards to the DOJ decision. I'm 6 reluctant to entirely close the record and 7 foreclose any additional comment until such time as that is concluded. 8 9 I mean, how is it that you would 10 wish to give me notice of the finality of that decision? 11 12 MS. CRISP: Well, the deal --13 the divestiture is not conditioned on the final 14 approval. It will be authorized to -- Aetna will be authorized to move forward with the 15 16 transaction with WellCare prior to -- at least 17 as I understand it. And, Michelle, if you want to supplement here, please do. 18 19 But my understanding is that it 20 is not -- there's not a barrier to moving 21 forward with the WellCare transaction. 2.2 In terms of the court approval, 23 we anticipate that there is a step that's 24 necessary that should happen within the next 25 week or so, and then we'll be able to move

1 forward.

2 THE COMMISSIONER: All right. 3 So the divestiture is something that you say 4 will not need to wait clearly until court 5 approval; is that fair? 6 MS. CRISP: My understanding. 7 Michelle, is that correct? 8 That is correct. MS. MATISKI: 9 And the court approval actually will not occur 10 until after we close. 11 We'll close the main 12 transaction, the acquisition of Aetna by CVS, 13 and then as soon as we possibly can, like 14 immediately after that we can close the sale to WellCare. 15 16 THE COMMISSIONER: All right. In light of all of that, I am going to keep --17 18 I'll keep the record open for another three days to allow -- I don't in any way suggest 19 20 that that means that's going to delay my review of the record and the evidence that's been 21 2.2 received, but I would like to keep it open 23 until -- when I say three days, I really mean 24 until Friday at 5:00, Friday at 5:00 p.m., 25 given the information that has been made public

today with regards to that DOJ decision and the issue with regards to the other transaction that will be appropriate for obtaining the DOJ settlement.

But I want to make sure all 5 parties have the opportunity to comment on that 6 7 should they -- I don't think it's really that material to what I have in front of me today, 8 but given the fact that this is a public 9 proceeding and there is information that came 10 11 out during the course of this proceeding, I do 12 want others to have the opportunity should they 13 wish to comment.

So that record will be held open until 5:00 p.m. on Friday, but, as I mentioned, I'll move forward with my review and begin nearing a timely decision on this Form A request.

So with that, is there anything
further from any of the parties in attendance?
Seeing none, we are off the
record. Thank you so much for coming today.
THE TRANSCRIPT OF PROCEEDINGS is
now complete. When transcribed, the original
of the transcript of proceedings shall be given

1	to Insurance Commissioner Doug Ommen. The
2	original exhibits shall be distributed as
3	follows: Exhibits A-C were retained by
4	Insurance Commissioner Doug Ommen at the time
5	of the hearing.
б	(Proceedings concluded at 10:35 a.m.)
7	(UNLESS OTHERWISE DIRECTED BY
8	COUNSEL OR THE PARTIES HERETO, THE STENOGRAPHIC
9	NOTES FOR THE FOREGOING PROCEEDINGS SHALL BE
10	DESTROYED AFTER A PERIOD OF 3 YEARS FROM THE
11	DATE OF TAKING OF SAID PROCEEDINGS.)
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

1	CERTIFICATE			
2				
3	I, the undersigned, shorthand reporter,			
4	a Notary Public of the State of Iowa, do he certify that I acted as the shorthand repor			
5	in the foregoing matter at the time and place indicated herein; that I took in shorthand the proceedings had at said time and place; that said shorthand notes were reduced to print under my supervision and direction by means of computer-aided transcription, and that the foregoing pages are a full and correct			
6				
7				
8	transcript of the shorthand notes so taken.			
9	I further certify that I am neither attorney nor counsel for, or related to or			
10	employed by any of the parties in the foregoing matter, and further that I am not a relative or			
11	employee of any attorney or counsel employed			
12	the parties hereto, or financially interested in the action.			
13	IN WITNESS WHEREOF, I have hereunto set my hand and seal this 26th day of October,			
14	2018.			
15	Kuist: S. Nills			
16	NOTARY PUBLIC			
17				
18				
19				
20				
21				
22				
23				
24				
25				

**\$1.1** 64:5 **\$38.5** 64:7 **\$6** 48:11

0

1

\$

**01** 31:13

1 27:8 28:23 62:18 63:11 1,100 20:3 **1.1** 33:24 10th 71:24 **14,000** 31:12 **15** 4:9,10 **16** 51:10 16th 24:11 **17** 4:3 **17A** 5:17 6:2 8:9 **185** 33:3 18th 51:23 **191** 6:5 1985 60:24 **1998** 17:14 19th 52:9 2 **2** 29:2 32:16 63:13.15

20 25:3 2000 58:15,16 2000s 22:1 2012 17:24 2015 60:15 2017 22:11 33:3 2019 56:21 **22nd** 52:10 26,000 31:11 **28** 25:1 3 **3** 6:5 32:19 34:3 63:16,17 **3's** 48:17 **30** 8:16 30th 71:24 **38.5** 33:22 **3rd** 59:7,8 4 **4** 34:6 35:20 39:25 64:14 65:23 44,000 61:1 **45** 8:16 **46** 60:2 **49** 4:4 5 **5** 40:4 45:19 48:11 65:25 68:10 521a.3(4)(a)(1-6) 14:8 26:23 **57** 4:5 6 **6** 45:22 46:17 68:12 69:10 **6.6** 33:4 **69** 23:5 7

**72** 4:11

2018 51:10 71:25

**750** 38:10 8 8 25:3 9 9,800 19:17 **97** 39:16 65:19 **98** 39:20 Α **A's** 59:12 **A-B** 15:14 **ability** 28:10 access 37:4 accounting 41:8 accuracy 26:7 accurate 61:14 accurately 8:22 achieve 60:4 acquired 69:4 acquisition 5:14 71:20 acquisitions 58:6,8 Act 6:2 acting 59:1 action 8:8 acts 50:12 acuity 20:6 acute 20:5 37:5 38:21 add 40:15 50:18 addition 6:11 65:11. 18 additional 34:1 39:20 40:15 46:9 51:6,18 55:25 71:19 address 8:12 13:20 19:5,21 21:2 26:15

35:24 36:1 42:14 48:3 53:3 54:10.18 62:11,14,16 addressed 31:19 32:8,13 42:12 63:14, 24 addressing 14:8 adherence 19:22 adjudication 21:16 adjusted 48:16,17 administrative 5:9, 25 6:1,5,6 7:16 admitted 7:18 15:1 advantage 69:3 advised 7:5 advisors 39:3.4 65:9 Aetna 5:15 10:17.20. 24 12:25 13:3 14:2 18:13 22:12,13,18, 19,22 23:6 24:13 27:18,19 28:13 29:18,23 30:4,9,24 31:12,25 32:9 33:21, 23 39:15 40:17,18,25 41:2 43:21 44:8,20 45:6 53:8,11,12 55:5 56:6,14 57:19,20,24, 25 58:13,15 59:23,24 60:11,13,19,22 64:2, 3,4,6 65:7,16 66:4,17 67:5,19 68:20 69:6 70:7 71:14 Aetna's 37:20 53:13 65:4 affidavit 19:10 25:13.23 26:2.6.10. 15,18 28:19,21 29:9 34:2 35:25 38:4 39:24 42:12 44:9 46:6,16 52:9 55:9 61:2,5,12,17,23

affidavits 14:22 41:23 42:2,23 43:13 44:1,14,24 45:12,15 66:12,24 67:12 68:3, 6

62:10 64:9 68:18

affiliates 29:18

Index: \$1.1..applicants

affirmed 6:19 afield 53:25 AG 55:17 agencies 48:4 agency 8:8 aging 21:3 agreed 32:4 agreement 22:10,11 23:3,4,17,20 32:1 39:6,9 56:15 **Aguirre** 40:19 ahead 9:15,17,19 10:1 11:3 13:10 15:13 49:14 allowed 7:3 amended 50:5.17.21 51:14.19 52:14 amendment 51:1 amount 33:5 analysis 29:8,15 30:15 69:7 analytics 37:21 69:6 and/or 51:15 **Angell** 17:22 **Ann** 12:24 announced 48:9 59:6 announcement 59:8 annual 38:12 56:18 antitrust 18:9 appeals 17:17 appearance 9:18 10:4 11:16 12:19

appeared 70:25

appearing 11:2

applicant 9:22 10:7 32:20 50:10 63:18

applicants 34:7,13, 17 64:15

application 5:12 11:4 25:24 41:24 47:2,11 49:22 50:5,9

applications 9:16 24:25

apply 27:1

**approval** 39:10,14, 15 54:24,25 58:5

approvals 25:2

**approve** 39:12,17 47:11 65:17

approved 11:5 49:1 65:19

approving 65:20

**approximately** 20:3 23:5,17 31:12 38:10 51:24 58:16 60:2 61:1 64:5,6

**April** 60:15

area 17:21

areas 18:3 68:23

arguments 7:12

arm's 39:4 65:7

Armstrong 11:18,21 47:21,24 48:20,25 49:6,11 70:16,21

arrive 7:7

assembled 12:16

assist 49:17

assistant 14:1 57:21

associate 17:18,23

assume 61:25

assurance 28:15

attend 7:3

attendance 71:18

attending 5:10

attest 43:15

attorneys 55:9,12

atypical 20:15

August 71:23

authority 5:21 authorized 11:6.11

avoid 38:21 awaiting 54:23

**aware** 49:9 50:12 64:24 70:18,19

В

**back** 12:15,22 22:1, 10 24:19 37:14 39:4 48:7 70:12 71:6

**background** 9:14 14:5 17:13 18:16 22:3 29:8 59:20,22

backgrounds 67:3

Bacon 43:22 44:10 66:7,19

**based** 28:21 31:14 33:25 39:23 41:25 42:24 43:13 44:15 45:13,18 46:3,15 52:14 55:4 63:9 64:8 65:21 68:4,25

basically 54:3

**bear** 33:9

begin 5:3 9:19 70:5

**behalf** 11:6 12:16,25 13:15

belief 50:2

Belin 10:19

**benefit** 9:18 11:20 18:25 21:5,11 37:9

benefits 35:22 60:2

Bertolini 40:17

Biddle 10:23 billion 23:5 33:3,4 48:11

biographic 67:12

**biographical** 41:22, 23 42:23 44:24 45:11 66:12,24 68:3,6 **bit** 14:4 17:11 18:15 21:8 24:8,20 29:8 31:21 33:15 34:24 38:24 58:12 60:7 65:3

blank 31:6

**board** 35:14 39:8 40:8,12,18 65:15,16

boards 39:10,11

**bodies** 36:10

Boratto 41:6 42:17

Bracken 41:12

break 8:15

Brennan 42:17

briefly 5:8 42:14

**bringing** 35:5 36:6, 13

broken 37:1

Brown 11:25 12:3 41:13

Brubaker 43:23 44:9 66:7,18

bucket 18:22

buckets 18:21

burden 69:23

**business** 5:4 18:9, 20 28:17 30:9 32:2,9 34:22 41:2 53:1,4 54:1,12 56:3,7

businesses 18:23 19:11 64:20

**buy** 48:7

#### С

call 16:19 57:3 called 16:24 21:6 57:11 calling 57:6 capabilities 37:21, 23

capacities 58:18 capital 33:21,23 64:4 capture 9:6,10,11 Index: application..communications

**care** 18:7,19,23 19:8, 13,22 20:3,6,7,8 21:2 36:4,15,18,25 37:4,7, 13 38:2,15,20 47:6,7 52:20 53:5 54:10 60:1,6 68:21,22 69:1, 7 70:4

carefully 26:7 61:12

Caremark 18:24 21:7,10 52:23 54:2

case 5:25

cases 6:18 7:17

**Casey** 44:11 45:8 66:20 67:21

cash 23:7 48:6

categories 19:6

category 19:7,12 21:5,21

**CEO** 40:17 41:3

**CFO** 41:5

chain 20:14

chairman 40:17

chance 8:18 12:12 35:25

change 22:17 34:21 52:18 53:10 64:25

changed 26:9 61:16

changing 54:2

**Chapter** 5:17 6:2,5 8:9

chief 41:8

**chose** 35:18

Christensen 44:21 67:6

Chronister 44:10 45:9 66:19 67:22 circumstances

50:13 **claim** 21:16

claims 36:9 clarify 52:12

clarity 51:18

Clark 41:7

45:2,15

**clinic** 20:3

clinical 21:17

41:5 53:22

co-pay 38:18

26:22

**cold** 20:14

collect 8:19

collective 14:14

combination 23:7

combined 35:23

combining 35:3

comment 7:4 64:1

commercial 18:5

commission 69:14

commissioner 5:1.5

6:9 8:7 9:25 10:8,25

15:4,12,16 16:15,16,

20 17:1 24:16 25:12,

47:1,14,18,22 49:14

56:22 57:2,5,8 58:20,

62:4,7 69:16 70:11,

18,20 26:4 46:21

51:7 52:16 53:24

54:20 55:8,14,21

24 59:1 61:21,24

14,24 71:7,15

commissioners

commonly 19:17

communications

59:14

12:14 13:1,4,16,19

71:17

comments 5:3 46:20

clinically 36:21

**close** 35:19 40:15

closing 23:9 56:10

**Code** 6:2,5 8:9 14:7

clear 29:25 44:15

clients 11:7 21:12,19

53:13 54:7,10,15,19

clerked 17:16

19:21

- community 68:25 69:1
- **companies** 22:9,24 24:13 29:22,23 31:9, 22 35:6 46:12
- **company** 18:5,10, 16,18,19 19:1,2 20:20 22:13,21 40:12 49:2 58:20 59:25 60:1 63:25

#### company's 29:14

competence 8:2 40:4 42:3,6 44:16 66:1,14

#### competency 68:7

- **competent** 43:3,18 44:6 45:4,16 67:3,15
- competition 29:4 31:7,8 32:10
- competitive 30:20, 21 31:24
- **complete** 46:19 56:5 69:12
- completed 58:9
- **complex** 20:16
- compliance 28:13
- computer 16:3,13
- concern 31:7,8,25
- **concerns** 30:20,21 32:6,8,10,15 53:3 54:18 64:23
- condition 32:20 63:18
- **conditioned** 39:10, 13 56:10
- conditions 20:6,17
- **conduct** 6:9,13 13:14 58:25
- conducted 6:1,14
- confidential 14:15 15:8,21 62:1
- confidentiality 15:2

**confirm** 25:6 26:7 28:2,6,23 32:14 34:2, 12 39:25 45:19 61:8 63:3,10 64:11 65:21 68:9

conformance 5:17

- connection 25:24 consent 32:3 55:6, 12
- consideration 23:6 71:19
- **considers** 27:9 29:2 32:19 34:6 40:4 45:23 63:17 64:15
- consistent 7:9
- consumer 58:24
- **contained** 49:25 50:4 61:13
- contents 49:22
  - contested 5:25
  - context 32:8
  - **continue** 10:2,3 11:15 22:25 27:10 28:10,15 35:9 53:10, 11 54:9,17 56:20 62:19 63:5,7 64:22 68:1
  - continuing 46:13
  - continuity 37:12
  - contracts 49:7 70:17
  - **control** 5:14 40:6 **controller** 41:8
  - **convenient** 20:23 36:21 37:3,8 38:15
  - cooperate 49:4
  - coordinated 14:19 coordination 36:3,
    - 14
    - **copies** 7:21 25:13 **copy** 25:14,18 61:22
    - Coram 20:18,20
    - corporate 35:11

- **Corporation** 5:13 17:10 40:11 **correct** 27:16 28:19, 20 33:6,7 34:19,23 51:10,13
- **cost** 19:24 38:11,20 48:1,21
- **costs** 36:20 38:5,10, 17 54:11
- **counsel** 9:22 10:15, 20,23 13:3,24 14:19 17:9
- counseling 19:20
- **country** 19:18 20:4 24:1,22 58:4 59:15
- **court** 6:7,19 8:17,21 9:6,9 15:10 17:16 54:23
- Courtney 12:8
- Coventry 58:8
- **coverage** 19:3,4 21:25 22:2 29:23,24 30:4,5,12 31:23 53:14
- **Crisp** 4:3,4 10:14,15 13:22 14:22 16:19,23 17:6,8 25:21 47:13, 19,24 48:2,24 49:5, 10 51:11,16,20,22,25 52:3,8,13,16 53:6 54:5 55:1,11,19,23 56:6,9,12,25 57:1 60:8 62:12 63:10,14, 24 64:10
- critical 38:1 68:24
- **Cross** 11:23 51:5,8, 13,17,21,24 52:2,11 55:24 56:8,11
- cross-examination 6:20 49:15
- **current** 17:6 22:11 27:21 40:16 41:5,11 57:18
- **CVS** 5:12,13 9:22 10:7,12,15 13:15,24 17:9,24 18:2,12,13, 17 19:14,16 20:9,11 21:6 22:4,19,20,24

- 23:4,7 25:9 28:8,12 29:17,22 30:4,11,24 31:11 32:25 33:2,10 35:4 39:18 40:11,24 41:11 42:11 43:5 46:10 47:25 48:5,12 49:1,3 55:5 58:10 59:12,13,21 63:25 69:5 71:12
- **CVS-AETNA** 13:20

D

cycle 56:18

- **D'ANTONIO** 44:21 45:7 67:6,20
- Dan 10:21,22
- **data** 29:12,13,14,16 36:7 37:15,16,19 53:17 69:6
- date 5:19 52:4 59:18
- dated 71:23
- **De** 41:13
- deal 38:25
- dealing 58:3,4,21
- deals 58:21
- **debt** 33:6,9,10,14 47:25 48:16,22
- **December** 22:10 59:7,8
- decision 8:7
- decision-maker 5:7
- declare 34:14
- Decoudreaux 41:13
- **degrees** 42:6 43:15, 16
- delivering 38:14
- **delivery** 20:15 52:20 70:6
- demonstrates 62:25
- **Denale** 43:8
- **dental** 30:18
- Denton 40:22 42:15

Index: community...divestiture

department 14:20 17:19.25 23:24 27:24 32:5 46:22,25 49:19 54:21 55:5,18 58:17 69:14,24 70:12 departments 24:2 28:14 58:3 59:15 deputy 58:19,23 **Derica** 42:17 describe 18:1 54:22 description 21:9 22:8 desires 54:18 detail 46:5 detailed 46:5 determination 8:13 development 21:15 Dickinson 9:20 13:12 difficult 9:5 diligence 23:18 direct 13:14 17:4 57:13 69:12 directly 18:23 29:13 41:2 directors 35:14 39:11 40:9,13 41:11 43:7,22 44:21 65:15, 16 66:6 67:6 discuss 22:6 43:19 discussed 28:19 62:12 discusses 68:19 discussing 63:21 disks 14:13,18 dispense 19:19 dispenses 20:11,20 district 6:7 diversified 60:1 divesting 56:2 divestiture 32:9 56:5,9

dividend 48:8,15

dividends 34:15

**division** 7:25 8:5 11:18,22,24 12:2,5, 11,13 47:20

division's 6:3 8:1

Doctor 42:16

document 25:21 26:13 62:1

**Documentary** 7:20

documentation 27:23 62:25 65:9,13

documented 32:3

documents 14:11 16:1

Dodge 17:22

domestic 22:14 24:12 25:10 27:9,14, 22 28:3,9,14 32:22, 23 33:12,13,17 34:8, 9,14,18,21 35:9,15, 17 40:6 43:20 60:8, 20 62:19,22 63:20,23 64:16,19 66:2 67:4

**Dorman** 41:14

**Doug** 5:5

**Drinker** 10:23

drives 14:13 15:1,5 25:11 62:6

**drug** 21:16,18,24 22:2 53:14

drugs 19:24 20:13

due 23:18

duly 16:24 57:11

# Ε

earlier 38:20 52:17 education 17:12 59:14 Edwards 17:22 effect 27:25 effective 37:25 effectively 37:19 effectiveness 37:22 efficiencies 52:18 efforts 53:2 electronic 16:8 elicit 16:11 emergency 38:19,22 employers 21:12 54:8 end 38:11 engaged 58:1 59:11, 13 enrollees 19:4 22:2 70:2,3 enrollment 56:18 ensure 6:12 28:14 36:16 37:16 50:11 entered 22:9 31:25 39:6 entities 21:13 54:9 63:1.4 entitled 6:22 31:15 entries 9:17 10:3 11:1,15 entry 12:19 episode 37:5 Eric 12:10 escort 7:5 establish 27:20 Eva 41:6 evaluate 27:1 29:20 evaluated 30:15 evaluating 8:3 29:19 evidence 7:15,16,17, 20 8:3 13:11 14:12 15:2,24 26:14 71:8 evidentiary 6:10 **evolve** 54:6,17 **evolved** 54:12 examination 4:2

6:20 13:14 17:4 57:13 69:13 excerpts 7:21 excited 47:4 53:22 excluded 7:15 excuse 71:23 execution 23:16 executive 40:24 42:10.20 43:7 44:7 45:6 66:17 67:19 exemption 31:2,16, 17,18 exhibit 4:8 16:8 exhibits 15:6,14,18, 20,23 24:15 existences 35:11 exists 22:23 expanded 40:14 expect 55:1,3,7 expectation 64:18 expected 23:9 38:5 expensive 20:13 37:9 38:15 experience 8:1 40:5 42:3,7 43:3,14,17 44:5,17 45:3,16 66:2, 14 67:2,15,16 68:4,7 expert 55:2 expertise 45:2 explain 5:8 20:10,18 23:15 33:8 36:4.22 37:13 38:3 46:2 explained 19:9 36:19 37:11 **explore** 53:22 exploring 53:18 extensive 43:17 extensively 41:21 42:22 43:11 extent 32:6 external 39:2

**extremely** 43:18 44:5

extraordinary 34:15

F

face 38:1 face-to-face 19:20

facilities 21:2 fact 25:25 27:2 60:16 61:8

factor 32:15,24

factors 14:7,9 27:1,6 62:11

**facts** 7:23,24 34:1 39:23 49:25 50:12, 16.25

fall 56:18

familiar 49:21

familiarity 41:18 42:19

family 17:20 22:24 24:13

Farah 40:19

Farber 9:24 10:5,9 11:10 52:4,6,10

favor 39:21

February 60:24

federal 17:16 23:23

feel 36:12,13

filed 24:1,24 49:18 50:9,10

filing 23:24

filings 18:10

final 7:11 8:8 26:1 46:20 54:25 57:5

**finally** 20:24 21:20 38:3 44:19 45:21 67:18 68:12

financial 29:12,17 32:19,21 33:1,16 35:4 39:3 63:18,19, 23 65:8

Index: dividend..fully

**financially** 33:2,20 64:3

find 37:3

Finucane 41:14

**firm** 10:6,11,19 12:1, 4 17:18,21

firmly 46:6

firms 39:3

Florence 4:3,4 10:14 13:22 16:19,23 17:8

flow 48:6

focus 70:6

focused 36:25

focuses 37:2

focusing 14:3,6 38:14

folks 70:8

Form 14:20 15:8,9, 22,23 24:5,10,14 49:18 50:1,10,17,21 51:1,9 59:12 62:1 69:20

formal 6:7 15:11

format 14:15,17

forms 23:25 24:25 58:21

formularies 21:15

forward 9:1 13:8 29:1 32:18 34:5 40:3 46:12 47:9 53:18 56:14 64:14 65:25

found 6:4 61:25

Fourth 20:18 38:3

frankly 37:8

Frohman 12:24

**front** 11:9 16:3 25:14, 22

fronts 38:7

fruition 53:21

full 9:4 21:10 57:15

fully 36:11

future 60:18 70:3

G

# gaps 19:21

gave 23:3 38:25

general 55:10,12

generally 6:7 7:17

generates 48:5

**give** 7:4 12:18 17:12 18:15 23:2 31:20 35:21,25 42:13 54:15 59:22 60:9 62:15

giving 8:24

goal 60:3

good 9:25 10:8,10 13:1,4

**Goode** 9:21

Gordon 12:8

government 14:1 21:13 54:8 57:22

graduated 17:14

Grant 43:23 66:7

great 37:9 70:1

greater 53:16

**Gregory** 4:5 10:16 13:25 57:6,10,17

**Group** 12:9

guess 55:15 57:6

gun-jumping 53:19

### Н

hac 9:16 10:21 11:2,5 half 23:11

hand 8:11 25:18

61:22

handed 26:3

handle 11:1

happening 41:5

happy 48:2

Hart-scott-rodino 23:24 hazardous 45:24 46:7 68:14 head 8:23 health 5:12,15,16 10:13,15 13:24 17:9, 25 18:7,13,14,17,19

20:2,6 21:12 22:20, 24 23:5 25:9 27:18, 19 28:8,12 29:17,22 30:11,18 31:6 33:11, 21,23 36:25 38:2 40:11,24 41:11 42:11 43:21 44:8,20 45:6 46:10 47:6,7 48:5 52:20 53:5 54:8,10 60:1,4,6,12,13,19,22 64:2,3,5,6 66:5,17 67:5,19 68:21 69:1,7 70:4 71:22

# Health's 32:25 healthy 21:19 37:2, hear 9:10 heard 7:1,10 52:19 54:22 59:20 60:7 65:22 66:5 hearing 5:11,21 6:9,

13,14 7:6 8:6 13:21 14:14 15:19 25:8

hearings 6:6,8 59:18,19

hefty 47:1

25

held 60:17 helping 37:6 38:1

60:3

**Hibbs** 12:3

high 28:16 42:6,8 43:4,15,16 44:4,16, 18 45:3,17 66:13 67:1 68:7,8

higher 20:14

highly 67:3,15

hired 65:8

historically 48:19

HMO 27:25 60:13,25

HMOS 63:2 64:1 hoc 9:23 hold 27:25 30:4,12

63:8

holding 49:2 63:25

holistic 36:15 holistically 37:18

home 20:22

hope 16:10

Hourican 42:18

huge 70:7

Humana 58:8

Hunter 4:4 11:25 49:12,16 51:4,14 70:23

L

idea 54:24

ideas 35:5

identification 15:15 identified 15:17 19:6

28:18 29:21 30:1 identify 27:13,17

35:21 37:6,18,23

illnesses 20:7

immaterial 7:14

impact 18:8 28:9 50:13 56:13

impacting 53:1

**Implementing** 6:3

important 69:18

importantly 38:13 69:18

improve 19:22 37:12

improvement 36:3

70:7 in-house 10:15 13:3

include 11:8

included 5:18

includes 18:7 21:12. 14 25:4

including 18:10 22:15 58:6

income 33:4

**Incorporated** 22:12

increase 30:22 31:13.14 48:8 52:17

increases 48:15

independent 65:8, 12

individuals 35:18 41:10,19 42:1,5 43:1, 2,6,10 44:16,24 65:1, 2 66:6,9,13,21,22 67:1,9,14,24 68:6

industry 53:4 58:12

information 5:19 14:18,24 16:11 17:12 18:16 22:4 28:22 29:11 33:25 36:11 37:17 39:24 42:24 45:18 46:4,15 48:4 50:2 59:21,22 60:5 61:13 64:8 65:22

infused 20:21

infusions 20:22.23

initiated 22:1

innovation 18:17 47:8

innovative 35:5

inpatient 20:23

instruction 9:14

insurance 6:3 11:22. 23 12:1,4,11,13 19:1, 2 21:21 24:2 29:4,20, 22 49:2 58:3,17,19, 23 59:1,15,25

insurance-buying 35:7 45:25 46:8 68:15

**insurer** 33:12.13 35:17 60:21 64:20 67:5

#### Index: future..issues

**insurers** 22:14 24:12 25:10 27:9.14.22 28:3,15 32:22 33:17 34:8,14,18 35:9,15 40:6 43:20 60:8 62:19,22 63:20 64:17 66:3

insurers' 28:10 32:23 34:9,21 63:23

intact 28:7

integrate 53:19

integrated 36:12

integration 37:15 46:11 53:16

integrity 28:17 40:5 42:4,9 43:4,17 44:4, 18 45:4,17 66:2,15 67:2,17 68:8

interactions 20:22

interest 34:11 35:7

interventions 37:24

involved 5:23 12:17

involvement 23:13

**lowa** 5:15,16 6:1,2,4,

6 8:8 12:10,13 14:7

15:8,9,22 24:12 25:5

26:19,22 27:12,18,19

48:1,22 49:2,4 60:12,

13,14,19,22,25 63:2,

6 64:1,6 66:5,18

67:5.19 70:3

irrelevant 7:14

issuance 27:11

issue 6:11 22:15

**issues** 5:21 6:10

29:5,9 39:19

issued 5:16

**Island** 17:21

29:4,24 31:17 33:21

43:21 44:8,20 45:6

23:18 24:3 58:7 59:5

45:14

68.25

55:17

46:7 48:21

interests 32:22

11:4 18:6,8,9 28:18 55:16 64:23 issuing 39:22 J James 41:7 January 24:11 51:10 56:19 jeopardize 32:21 63:19 Jim 11:21 John 11:25 join 55:12 joined 17:21,24

joining 58:15

**Joint** 5:12

journey 18:18

judge 17:16

judicial 7:23

jump 40:3 65:25

jumping 64:14 67:4

Justice 23:25 32:5 54:22 55:5,18

# Κ

Karen 40:24

keeping 37:2,25 Kessler 44:10 66:19

**key** 36:5

keys 36:23

**Kim** 11:23

knowledge 7:25 8:2 41:25 50:2,7 66:16

Konz 12:10

Krane 10:21,22 11:10 71:12,13

#### L

large 16:6 59:24

63:25 largely 22:16,25 53:7 lastly 38:23 45:5 latest 52:7 law 7:9 10:6,19 12:1, 4 17:14,15,17,21 39:3 lawyers 65:12 lead 38:21 41:1 led 23:19 **Lee** 45:8,13 67:21 left 8:22 9:19 13:23, 25 legal 5:21 13:24 17:9, 25 legislative 58:2

list 45:13

18:5

8

literacy 19:23

localized 70:6

located 31:5

location 5:20

**Locke** 10:6,12

long 8:16 46:11

looked 29:16

Lord 10:6.12

38:9,20

LS2 12:9

Ludwig 40:19

Lynch 12:6 40:22,25

Μ

made 35:18 49:8

Maggie 12:3

maintain 35:10

maintained 60:17

make 6:16,25 8:13

12:19 16:4 34:20

47:15 61:12

50:14 53:2 70:18

lot 37:2 39:4 68:19

lower 20:6 36:20

long-term 21:2 53:7

litigation 17:18,23

local 9:21 10:19 69:1,

length 39:5 65:7

lessen 29:3

letter 71:22 level 23:23 33:11

35:17

**levels** 28:16 42:8 43:4 44:4,16,18 45:3, 17

license 30:5,12 60:17

licensed 60:14,23 63:1,2 64:1

licenses 27:11,21,24 28:1,2,7 63:5,8

licensure 28:4,11 62:20,23

life 37:24

lifetime 37:17

lifted 22:23

limited 5:19

lines 6:15 29:20,21

liquidate 34:18

30:3,9,15,20 31:1,19

limit 7:8

32:13

makeup 40:8

21:18

management 21:11 35:15 64:25

manager 18:25 21:6

managing 18:4 manner 7:9

Mark 9:20 40:17

**marked** 15:5,8,13,14, 21

Marked/offered/ admitted 4:8

market 48:7 54:17 58:22,24

marking 15:11

Maroney 44:9 45:8 66:18 67:21

Martino 4:5 10:16 13:25 14:22 57:6,10, 15,17 62:9 70:10,19 71:3

Martino's 61:23

material 34:21 35:13 50:16,24

materially 28:9

Matiski 13:2

Matt 10:18

**matter** 5:2,12 14:10, 21,23 24:7 25:13 61:3 69:17

matters 58:1,2,3,5

Mcdermott 10:18,19

Mcelhaney 12:12,13

Mcintosh 42:16 mechanics 55:3

mechanism 20:16

Medicaid 56:17

medical 36:8,9 37:16 53:17

Medicare 19:3,4 22:2 30:17,19 31:5, 21,23 32:7,14 56:2

medication 19:19, 22,23

**medications** 20:12, 21

**meet** 10:8 28:10,15 54:6 63:8 64:22

meetings 24:3

member 7:6

Index: issuing..motions

members 6:21,24 21:19 40:13,18 54:16 56:13,14,21 60:3,4 61:1

membership 60:16

mentioned 11:9 21:23 51:8 52:17

**merger** 22:10 23:3,4, 17,19 39:5,9 52:25 54:4

mergers 58:6

Merlo 41:14 42:15

met 27:3,21 28:24 34:25 40:1 45:19 46:1,17 63:11 64:12 65:23 68:10,16,18 69:10

Michelle 13:2

mid 22:1 48:17

million 33:22,24 38:10 60:2 64:5,7

Millon 41:15

mind 7:13

minimize 56:12

minimum 28:3

minor 20:7

minute 19:10

**Minuteclinic** 19:25 20:2

Minuteclinics 20:5

minutes 6:16 8:16

misleading 50:20

modify 61:18

Moffatt 43:8

momentarily 52:5

months 59:2

Moriarty 42:16

**morning** 10:10 13:1, 4

motion 10:21 motions 6:10 9:23 10:3 move 13:8 21:4 29:1 31:4 32:18 34:5 63:15

**moved** 14:12

moves 56:14

**moving** 43:5,19

## Ν

**NAIC** 29:13

national 59:25

nature 5:20

needing 16:13

negotiated 65:7

negotiations 38:24 39:1,5 65:4

**net** 33:3,4

Nodding 8:23

nonconfidential 14:16

nonresponsive 8:24

note 46:10

notes 8:18

**notice** 5:11,18 7:23, 24 25:7,9

notified 6:23

number 27:8 32:16, 19 34:3 39:2 58:5.17. 18 59:19 60:23 62:18 66:11

Nyemaster 9:21

#### 0

objection 7:18 15:19 objections 7:18 15:17 obligated 33:13 **obligation** 33:10,12 observing 12:9 obtained 29:12

**obtains** 29:13 occupied 40:16 occurred 59:18 **October** 51:23 offer 29:23 30:5,12 31:23 71:18 offered 71:9,17 offering 21:25 54:14 offers 30:4 officer 5:7 6:8 8:6 41:8 officers 40:24 42:11, 20 43:7 44:7 45:6 66:17 67:19 official 7:23 Olson 44:11 66:20 **omitted** 50:16 **Ommen** 5:5 Omnicare 20:24 21:1 opening 5:3 6:16 operate 22:25 28:16 43:16 44:17 45:3,17 **operated** 42:8 43:4 operating 44:4 60:25 operations 64:25 opportunities 37:7 53:23 60:18 opportunity 7:1,11 12:18 26:18,25 31:20 35:21 42:13,21 45:12 46:25 53:16 59:22 60:9 61:22 62:10,15 69:5 70:1,2

order 11:4 32:4 37:16

organization 35:23

55:6,12 56:12

orderly 6:13

orders 6:12

originals 7:22

outreach 59:13

overseeing 58:22 overwhelming 39:14 overwhelmingly 65:19 owned 22:20 owning 22:18 Ρ **Palmer** 17:22 paper 69:20 papers 16:7 paperwork 65:10 parent 33:11 40:11 Parle 41:13 part 12:23 19:3,4 21:24,25 24:13 31:21,23 32:1,7,9,11, 14 53:1,4 56:2 69:9 participate 6:22 parties 6:15,17 7:10, 11 8:18 32:4 71:9 partner 17:23 partnering 69:4 party 12:17 71:10 **passed** 48:22 passing 47:25 path 47:9 patient 36:15,18 37:17,25 38:20 patient's 37:24 patients 18:24 19:21,23 20:16 36:8, 11 37:1,4,10 38:15, 16 pay 23:5 paydown 33:14 paying 38:18 payments 48:21

overlap 30:7,13 32:7

**PBM** 21:6 52:24 53:8, 11 54:1 pending 10:3 25:3,4 Pennsylvania 58:17 59:2 percent 30:25 31:13 39:16,20 65:19 person 9:7 perspective 65:5 pertains 24:12 pharmacies 19:18 pharmacists 19:19 pharmacy 5:13 18:17,24 19:14,16 21:1,5,11 22:19,20 36:7 37:15 43:5 53:17 physicians 20:8 pick 8:22 place 22:16 23:10 plan 21:24 36:18 47:25 54:14 56:16, 19,20,21 plans 21:12,15 28:9 34:7,13,18,20 53:20 54:8 64:16,24

**pleasure** 58:10,25 66:10 67:11

point 38:1 54:16

points 23:2 37:19,23

policyholders 32:23 34:10 48:1.23

population 21:3 35:8

position 17:7

positive 67:16

post-transaction 28:7 35:10 38:12 40:6 63:4 64:20,21

potential 47:6

**pounds** 69:19

practiced 17:17

Index: move..proceeding

precise 52:4 prejudice 32:22 35:3 prejudicial 45:24 68:14 preliminary 14:10 premium 31:12 premiums 31:9 preparation 49:17 **prepare** 65:12 prepared 16:4 25:23 27:5 61:2 preparing 26:17 59:12 prescription 21:16 53:13 presence 69:8 present 6:17 29:9 presented 5:22 8:4 9:5 24:16 president 14:1 40:25 57:21 presiding 5:7 6:8 pretty 55:4 prevent 16:12 **previously** 5:16 62:2 primarily 58:2 primary 8:6 18:3,21 20:8 **prior** 23:16 58:15 59:5 pro 9:16,23 10:21 11:2,4 proactive 28:13 problem 8:25 procedural 55:16 Procedures 6:2 **proceed** 5:4 9:15 11:19 13:10,17 17:2 47:23

proceeding 5:6,24, 25 6:4 12:18 13:7

53:25

proceedings 11:12 16:7 50:11

process 5:9 6:22 23:23 56:2

products 54:17

profile 36:7,8

program 21:25

programs 21:17

proper 25:6

proposals 34:7 64:16

proposed 58:9

**provide** 18:23 19:8, 12 20:5 21:8 22:7 36:14 39:24 46:21 51:17 52:5 53:12 60:6 69:5

provided 22:3 25:10 28:22 29:16 48:3 64:9,10

providers 36:17

**providing** 14:4 60:1, 4

**public** 6:21,24 7:6 14:16 15:8,22 22:13, 18,21 34:10 45:25 46:8 48:15 59:8 62:1 68:15 71:17

publicly 59:6

purchase 5:14

purposes 8:8

Pursuant 22:11

# Q

qualify 31:1

quality 28:15 36:3

query 8:12

**question** 8:10 9:4,7 49:7 51:6 54:21 55:15,25

questioning 7:8 15:25

<b>questions</b> 47:15,17, 20 49:13 52:24 55:22 56:23 70:13,15,23,24 71:2		
R		
raise 8:11		
range 21:10 48:12		
rates 58:21		
rating 48:4		
ratio 48:17		
reached 37:4		
ready 9:14		
realize 38:10		
Reath 10:23		
rebates 54:15		
recall 52:3		
receipt 15:18		
receive 23:8		
<b>received</b> 7:21 15:20, 23 16:9 24:24 25:2,9 62:2 71:21,23,24		
recent 51:1		
receptionist 7:5		
recognize 13:13 68:24 69:23		
recognized 13:9 15:3 19:17		
recognizing 10:2		
<b>record</b> 5:2 7:19 8:12, 14 9:18 11:20 12:23 44:3 46:11,13 52:12 57:16		
reduction 38:16		
refer 20:12		
reference 55:9		
referencing 51:14		
referring 16:1		
reflecting 27:24		
regard 34:8		

regulate 52:23 regulated 49:1 regulation 58:20 Regulator 15:9,22 regulators 24:4 49:4 regulatory 15:9 18:6,8,10 23:22 58:1, 2.4 59:13 Reinecke 45:8 67:21 relates 52:25 relations 14:2 57:22 relationship 53:8 relative 6:4 relaxed 7:16 relevant 7:17 relocated 17:20 remain 22:16 28:7 41:1 50:6 **Reorg** 12:7 repay 47:25 repeat 9:12 repetitious 7:14 replaced 65:2 report 29:23 31:9 33:22 **reported** 30:9,24 33:3,21,23 **reporter** 6:19 8:17, 21 9:6,9 12:7 15:10, 15 reporting 41:2 reports 31:11 represent 10:7,12 representations 50:25 representing 12:1,4 repurchases 48:10, 14 request 14:12,25 47:11

requests 24:4 returned 48:16 require 20:13 26:10 revenues 33:3 61:18 **review** 8:18 23:22 requirement 27:8 25:4 26:6,19 29:24 28:23 29:2 32:18 30:6 42:25 43:13 44:15 45:1,14 55:18, 34:3,6,25 35:20 20 61:12 65:9,13 39:25 40:4 45:19,22 69:20 46:1,17 62:17 63:11, 13,17 64:11,14 reviewed 27:23 29:5 65:23,25 68:10,12,16 41:22,23 42:22 43:12 69:10 44:1,14,23 45:11 requirements 5:17 62:24 66:12,24 67:12 27:10 28:4,11 62:20 68:2 69:19 63:8 64:22 reviewing 42:1 47:3 resign 35:18 68:5 resignation 65:2 revise 26:10 resigning 41:6 Rhode 17:21 resources 47:3 60:5 **Rice** 42:17 rise 23:3 38:25 respect 14:23 23:1 24:1,6,21 25:7 27:21 **rising** 54:10 29:17 30:19 32:7,15, **risk** 37:18,23 24 33:6,13 35:22 39:5 40:1,10,21,23 **Roberts** 42:16 41:18 44:19 45:5 46:22 53:13 61:3 robust 28:13 37:20 63:13 64:16,19 69:15 39:1 respectfully 14:25 role 5:6 14:5 18:2 47:10 23:13,22 41:1,6,7 57:24 58:13 59:4 respective 11:7 roles 44:6 58:13 responding 24:4 room 7:6 12:15,22 responses 52:14 13:7 38:19,22 responsibilities rule 6:10 9:15 18:2 57:23,25 rules 5:22 6:3 7:15 responsibility 18:4 rulings 6:12 restate 9:1 runs 8:17 **restated** 50:5,17,21 51:15,19 52:15 **Ryan** 12:6 restatement 51:2 S restrictions 15:3 result 36:20 38:8 sale 54:16 retail 18:8 20:2 satisfied 34:3 **retailer** 18:19 satisfy 27:10 28:3 62:19 retained 39:2

savings 38:11

Schapiro 41:15 school 17:14,15 screenings 20:7

seats 40:15,16

Section 14:7 26:23

seeking 9:8 11:3

sell 32:1

selling 56:7

senior 13:23 17:9 35:14 40:23 65:1

sense 56:4

**separate** 19:11 35:10 65:8,12

September 71:24

serve 5:6 43:6

served 58:16,19

serves 13:23,25

**service** 53:11 54:7 56:14,20

services 21:1,11 53:12 56:15 58:24

serving 8:6 58:25 60:2

set 14:7 24:14 34:1 46:16 62:10

sets 14:11

settlement 54:23

shaking 8:23

**share** 30:23,25 48:10,13 69:14

shareholder 23:8 39:14 48:8,14 65:15

shareholders 22:18 23:6 39:16,19,21 48:15 65:18

shares 48:7

she'll 41:1

shift 36:24 37:7

shifted 22:23 23:22

Shifting 42:10

short 8:15 shortly 55:7 side 39:15,18

sides 39:2

signature 26:1 61:9

signed 23:21 25:24 26:6,11 61:11,17 71:22

significant 18:11 45:2 69:3,6,8

signing 23:19

Silverscript 19:2 21:21,23

similar 24:25

simply 12:20

simultaneously 9:8

Sir 61:2 65:21

sit 61:18 site 38:20

sites 36:21 37:7

sits 8:22 sitting 13:23 25:22

situation 38:21

**skip** 63:15

Sloma 44:22 67:7 slowly 8:21

small 31:10

**SNL** 29:12,17

**sort** 53:2 **sound** 33:2,20 64:4

speak 8:20

speaking 9:8 40:10

specialized 7:25 8:2

specialty 20:9,11,12

specifically 22:5 23:12 26:22 41:9 spectate 12:21

spend 21:18

spent 59:9
sponsor 9:23 10:20
stability 32:21 63:20
stack 16:7
staff 59:14 69:18

standalone 19:3 21:24 32:1

standards 28:16

**start** 17:11 18:13 19:7 27:8 29:10 40:7 41:11 54:14 60:11 62:17 66:4

starting 56:19

**state** 14:1 27:11 28:4 55:9,11,17 57:15,21 60:14,25 62:20 63:2, 6

stated 7:19

statement 49:18 50:1,10

statements 6:16 50:4,14,20,25

states 24:22 25:1,3

statute 26:19 statutes 5:22

**statutory** 31:2,17,18 64:22

step 41:7

**Steve** 13:13

Steven 10:11

stock 23:7 39:20,22

stockholder 39:8

straightforward 55:4

strength 33:1,16 35:4 63:23

**strong** 66:15 67:2, 15,17

**structure** 22:12,16, 22

**subject** 6:20 7:18 50:11

submission 63:15 submissions 14:14, 16

**submit** 15:10

**submitted** 6:11 14:21 24:6,11 25:12 26:14 41:24 49:23 51:9 55:6

subsequent 51:14

subsidiaries 22:15

substance 26:15

substantial 42:7 43:3 44:5,17 45:16 48:6

substantially 29:3

successful 46:11

summer 17:24

supplement 20:8 31:5 37:22

**supplemented** 50:6, 18,22 51:15,21

**surplus** 33:22,24 64:4

**suspend** 48:10,13, 14

swear 16:22

Swift 41:15

**sworn** 6:18 16:21,25 57:7,9,12

**system** 36:25 60:6 68:21 70:6

### Т

#### table 11:19

tailored 36:21

talk 18:12 22:4 23:12 24:5,19,20 30:14,16 31:20 40:21 41:9 43:20 45:21 58:12 59:3 60:10 66:1 67:18

talked 46:4

Index: Schapiro..trans

33:17 40:7

talks 62:18

team 47:16 65:1

terms 53:10 54:2,3

testify 27:5 52:19

testimony 7:4 8:23

9:6,11 46:19 47:19

51:9 57:3 63:9,10

testified 16:25 57:12

technical 8:2

tend 20:12

59:19

71:3,19

thereof 49:22

thing 46:10

things 53:9

25:11 62:6

timely 7:19

times 48:18

timing 54:25

title 30:18 57:18

today 9:21 11:7

13:19 14:4,9,12

25:8 26:11,16,20

50:6 61:19 62:12

64:9 65:23 70:25

today's 5:24 11:12

50:11 53:25

total 29:19

touch 20:14

trans 54:3

18:12 22:6,25 24:16

27:5,15 28:22 46:20

tiny 31:14

Tim 10:5

thoughts 8:19

thumb 14:13 15:1,5

time 5:20 6:23 13:9,

12 15:1 23:17 26:11

9 61:17 69:17 71:16

47:2 54:13 57:7 59:7,

talking 26:19 27:14

transaction 13:20 14:5,6 22:5,8 23:1,14 27:2 29:3 33:6 35:19 36:6,20 37:12 38:4,9, 24 39:12 40:1 45:23 46:13,23 47:5 49:1,8 56:10,13 58:11 59:3, 6,10,16 65:4,17,20 68:13 69:15,20 70:17 71:10	unit 41:2 Unitypoint unreasonab 64:17 V values 36:5
transactions 18:11 65:6	variety 18:6 22:14
transform 47:6 68:21 transformation 47:7 52:20	version 52:1 vice 9:16,23 11:2,5 14:1 5 view 36:15
transformed 70:5 transition 56:15 true 50:1,6 61:14 turn 61:7 70:11 71:6 twelve 40:13 41:12, 18 type 20:15	virtually 59: visit 38:19 visually 16:4 Volume 6:5 voted 39:11, votes 39:8.6
<b>types</b> 24:25 <b>typically</b> 48:11	voting 39:16
typically 48:11 U ultimate 40:11 60:3 unable 9:10 unacceptable 8:24 unanimously 39:12	W wait 9:3 wanted 52:1 ways 37:3 week 52:1 Weldon 41:2
typically 48:11 U ultimate 40:11 60:3 unable 9:10 unacceptable 8:24	W wait 9:3 wanted 52:1 ways 37:3 week 52:1 Weldon 41: Wellcare 32 White 41:16 Whitmer 4:3
typically 48:11 U ultimate 40:11 60:3 unable 9:10 unacceptable 8:24 unanimously 39:12 65:17 underneath 19:12 understand 49:3 52:21 understanding 24:17 31:15 64:19 Understood 52:2	W wait 9:3 wanted 52:1 ways 37:3 week 52:1 Weldon 41: Wellcare 32 White 41:16
typically 48:11 U ultimate 40:11 60:3 unable 9:10 unacceptable 8:24 unanimously 39:12 65:17 underneath 19:12 understand 49:3 52:21 understanding 24:17 31:15 64:19	W wait 9:3 wanted 52:1 ways 37:3 week 52:1 Weldon 41:7 Wellcare 32 White 41:16 Whitmer 4:3 10:10,11 11: 13:13,18 15: 18 17:3,5 25 47:12 57:4,1 62:3,5 70:9,7

	16.1 12 71.4 6
71:22	16:1,12 71:4,6 work 42:21 45:12
<b>ble</b> 34:9	53:11 54:9 57:20
IDIE 34.9	69:24
1	worked 41:20 43:11 59:17 68:2
	working 41:25 43:14
5	58:10 59:11 66:10,23 67:11 68:5
6 21:17	wrapped 55:17,19
2:15	x
3 10:21   57:21	<b>XVIII</b> 30:18,19
9:9	Y
	Yale 17:15
6:4	year 23:11,18 38:11
5	48:11 56:16,19,21
1,17,21	<b>years</b> 42:7 44:5 58:18 60:23 66:11,
65:15	14,23 67:2,11,15
16,19	68:4,7,20
V	<b>York</b> 17:17
. 4 4	
::11	
1:16	
32:2 56:3,7	
6	
:3,5 9:24	
1:10 5:7 16:14,	
25:17	
,14 61:21 9,15 71:2,	
:1,4	
:18	
6:18 7:10	
,22 14:3	